Pro-C-Dure 6

Drug overview for PRO-C-DURE 6 (triamcinolone acetonide):

Generic name: TRIAMCINOLONE ACETONIDE (trye-am-SIN-oh-lone AS-e-toe-nide)
Drug class: Glucocorticosteroids
Therapeutic class: Endocrine

Triamcinolone is a synthetic glucocorticoid.

Triamcinolone is used principally as an anti-inflammatory or immunosuppressant agent. Because it has virtually no mineralocorticoid properties, the drug is inadequate alone for the management of adrenocortical insufficiency. If triamcinolone is used in the treatment of this condition, concomitant therapy with a mineralocorticoid is also required.

DRUG IMAGES

No Image Available

The following indications for PRO-C-DURE 6 (triamcinolone acetonide) have been approved by the FDA:

Indications:
Acquired thrombocytopenia
Acute exacerbation of multiple sclerosis
Acute gouty arthritis
Acute lymphoid leukemia
Acute rheumatic carditis
Adrenocortical insufficiency
Adrenogenital disorder
Angioedema
Ankylosing spondylitis
Aspiration pneumonitis
Atopic dermatitis
Autoimmune hemolytic anemia
Berylliosis
Bursitis
Cerebral edema
Contact dermatitis
Crohn's disease
Dermatitis herpetiformis
Diamond Blackfan anemia
Erythema multiforme
Erythroblastic anemia
Exfoliative dermatitis
Hodgkin's lymphoma
Humoral hypercalcemia of malignancy
Hypersensitivity drug reaction
Idiopathic thrombocytopenic purpura
Inflammatory bowel disease
Juvenile idiopathic arthritis
Laryngeal edema
Loffler syndrome
Mycosis fungoides
Nephrotic syndrome
Non-Hodgkin's lymphoma
Ocular inflammation
Organ transplant rejection
Pemphigus
Post traumatic osteoarthritis
Psoriasis
Psoriatic arthritis
Pure red cell aplasia
Rheumatoid arthritis
Sarcoidosis
Serum sickness
Status asthmaticus
Synovitis due to osteoarthritis
Synovitis
Systemic dermatomyositis
Systemic lupus erythematosus
Tendonitis
Tenosynovitis
Thyroiditis
Transfusion reaction urticaria
Trichinosis
Ulcerative colitis

Professional Synonyms:
Aase syndrome
Acquired hemolytic anemia due to antibodies
Acute articular gout
Acute exacerbation of MS
Acute gout attack
Acute gout flare
Acute lymphatic leukemia
Acute lymphocytic leukemia
Acute lymphogenous leukemia
Acute relapse of MS
Acute relapse of multiple sclerosis
Acute severe asthma attack
Acute severe asthma
Acute uratic arthritis
Adrenal cortical hypofunction
Adrenal failure
Adrenal insufficiency
Adrenocortical hypofunction
Adrenogenital syndrome
Allergic reaction to blood or plasma
Allergic transfusion reaction
Anemia lymphatica
Angioneurotic edema
Arthritis deformans
Arthrosis deformans
Asthma with status asthmaticus
Atopic eczema
Atrophedema
Axial spondyloarthritis with radiographic sacroiliitis
Bannister's disease
Bekhterev's arthritis
Bekhterev's disease
Bekhterev's spondylitis
Besnier-Boeck-Schaumann disease
Besnier-Boeck-Schaumann syndrome
Blackfan Diamond syndrome
Blistering skin disease
Boeck's disease
Boeck's sarcoid
Brain edema
Bullous dermatitis herpetiformis
Colitis ulcerativa
Congenital erythroid hypoplastic anemia
Congenital hypoplastic anemia
Congenital pure red cell aplasia
Constitutional erythroid hypoplasia
Deficiency in bone marrow erythroblasts
Dermatitis venenata
Disseminated lupus erythematosus
Disseminated neurodermatitis
Drug hypersensitivity reaction
Drug-induced hypersensitivity reaction
Drug-induced hypersensitivity
Erythema exfoliativa
Erythema polymorphe
Erythroblastopenia
Erythroderma exfoliativa
Erythrogenesis imperfecta
Exfoliative eczema
Exfoliative erythroderma
Giant urticaria
Hebra's disease
Herpes iris
Hodgkin's disease
Hypercalcemia associated with cancer
Hypercalcemia associated with malignancy
Hypercalcemia of malignancy
Hypoadrenalism
Hypocorticoidism
Immune thrombocytopenia purpura
Inflammation of the synovial membrane
Inflammation of the synovium
Juvenile RA
Juvenile rheumatoid arthritis
Loeffler syndrome
Loffler's syndrome
Lupus erythematosus syndrome
Lymphoblastic leukemia
Malignant hypercalcemia
Marie-Strumpell disease
Marie-Strumpell spondylitis
Mendelson's syndrome
Milton's disease
Multiple sclerosis exacerbation
Nodose rheumatism
Non-Hodgkin's type lymphoma
Ophthalmic inflammation
Organ transplant rejection reaction
Periodic urticaria
PIE syndrome
Post infectious thrombocytopenia
Post traumatic OA
Post-traumatic osteoarthritis
Posttraumatic osteoarthritis
Psoriasis arthropica
Psoriatic arthropathy
Purpura hemorrhagica
Quincke's disease
Quincke's edema
Regional enteritis
Regional ileocolitis
Rheumatic arthritis
Rheumatic gout
Rheumatoid spondylitis
Rhizomelic spondylitis
Rhizomelic spondylosis
Schaumann's syndrome
Secondary thrombocytopenia
Serum sickness-like reaction
Severe asthma exacerbation
Simple pulmonary eosinophilia
Spondylosis deformans
Strumpell-Marie disease
Suprarenal failure
Synovitis due to OA
Synovitis with osteoarthritis
Tendinitis
Tendinous synovitis
Tendosynovitis
Tendovaginitis
Tenontolemmitis
Tenontothecitis
Tenovaginitis
Transplant rejection
Trichinella spiralis infection
Trichinellosis
Trichiniasis
Urticaria tuberosa
Urticarial transfusion reaction
Werlhof's disease

The following drug interaction information is available for PRO-C-DURE 6 (triamcinolone acetonide):

Contraindicated
Severe
Moderate

There are 4 contraindications. These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.

Drug Interaction	Drug Names
Efalizumab; Natalizumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Natalizumab,(1-3) efalizumab,(4) immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of natalizumab(1-3) or efalizumab(4) with immunosuppressives or immunomodulators may result in an increased risk of infections, including progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV). PREDISPOSING FACTORS: Previous JCV infection, longer duration of natalizumab treatment - especially if greater than 2 years, and prior or concomitant treatment with immunosuppressant medication are all independent risk factors which increase the risk for PML.(1,5) The FDA has estimated PML incidence stratified by risk factors: If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment less than 25 months, incidence <1/1,000. If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment less than 25 months, incidence 2/1,000 If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 4/1,000 If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 11/1,000. PATIENT MANAGEMENT: The US manufacturer of natalizumab states patients with Crohn's disease should not receive concurrent immunosuppressants, with the exception of limited overlap of corticosteroids, due to the increased risk for PML. For new natalizumab patients currently receiving chronic oral corticosteroids for Crohn's Disease, begin corticosteroid taper when therapeutic response to natalizumab has occurred. If corticosteroids cannot be discontinued within six months of starting natalizumab, discontinue natalizumab.(3) The US manufacturer of natalizumab states that natalizumab should not ordinarily be used in multiple sclerosis patients receiving immunosuppressants or immunomodulators due to the increased risk for PML. Immunosuppressives include, but are not limited to azathioprine, cyclophosphamide, cyclosporine, mercaptopurine, methotrexate, mitoxantrone, mycophenolate, and corticosteroids.(3,6) The UK manufacturer of natalizumab states that concurrent use with immunosuppressives or antineoplastic agents is contraindicated.(1) The Canadian manufacturer of natalizumab states that natalizumab should not be used with immunosuppressive or immunomodulatory agents.(2) The US manufacturer of certolizumab states that concurrent therapy with natalizumab is not recommended.(7) DISCUSSION: Progressive multifocal leukoencephalopathy has been reported in patients receiving concurrent natalizumab were recently or concomitantly taking immunomodulators or immunosuppressants.(1-5,8,9) In a retrospective cohort study of multiple sclerosis patients newly initiated on a disease-modifying therapy, use of high-efficacy agents (alemtuzumab, natalizumab, or ocrelizumab) resulted in the same risk of overall infections as moderate-efficacy agents, but there was an elevated risk of serious infections (adjusted hazard ratio [aHR] = 1.24, 95% confidence interval (CI) = 1.06-1.44) and UTIs (aHR = 1.21, 95% CI = 1.14-1.30).(10)	TYSABRI
Talimogene laherparepvec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Talimogene laherparepvec is a live, attenuated herpes simplex virus.(1) CLINICAL EFFECTS: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Talimogene laherparepvec is contraindicated in immunosuppressed patients.(1) The magnitude of immunocompromise and associated risks due to immunosuppressant drugs should be determined by a physician. DISCUSSION: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1)	IMLYGIC
Desmopressin/Glucocorticoids SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Glucocorticoids increase the risk of hyponatremia.(1-4) CLINICAL EFFECTS: Concurrent use of glucocorticoids may increase the risk of hyponatremia with desmopressin.(1-4) PREDISPOSING FACTORS: Predisposing factors for hyponatremia include: polydipsia, renal impairment (eGFR < 50 ml/min/1.73m2), illnesses that can cause fluid/electrolyte imbalances, age >=65, medications that cause water retention and/or increase the risk of hyponatremia (carbamazepine, chlorpromazine, lamotrigine, loop diuretics, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants). PATIENT MANAGEMENT: The concurrent use of systemic or inhaled glucocorticoids with desmopressin is contraindicated.(1-4) Desmopressin may be initiated 3 days or 5 half-lives after glucocorticoid discontinuation, whichever is longer. If concurrent use is deemed medically necessary, make sure serum sodium levels are normal before beginning therapy and consider using the desmopressin nasal 0.83 mcg dose. Consider measuring serum sodium levels more frequently than the recommended intervals of: within 7 days of concurrent therapy initiation, one month after concurrent therapy initiation and periodically during treatment. Counsel patients to report symptoms of hyponatremia, which may include: headache, nausea/vomiting, feeling restless, fatigue, drowsiness, dizziness, muscle cramps, changes in mental state (confusion, decreased awareness/alertness), seizures, coma, and trouble breathing. Counsel patients to limit the amount of fluids they drink in the evening and night-time and to stop taking desmopressin if they develop a stomach/intestinal virus with nausea/vomiting or any nose problems (blockage, stuffy/runny nose, drainage).(1) DISCUSSION: In clinical trials of desmopressin for the treatment of nocturia, 4 of 5 patients who developed severe hyponatremia (serum sodium <= 125 mmol/L) were taking systemic or inhaled glucocorticoids. Three of these patients were also taking NSAIDs and one was receiving a thiazide diuretic.(2) Drugs associated with hyponatremia may increase the risk, including loop diuretics, carbamazepine, chlorpromazine, glucocorticoids, lamotrigine, NSAIDs, opioids, SSRIs, thiazide diuretics, and/or tricyclic antidepressants.(1,3-4)	DDAVP, DESMOPRESSIN ACETATE, NOCDURNA
Nadofaragene Firadenovec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Nadofaragene firadenovec may contain low levels of replication-competent adenovirus.(1) CLINICAL EFFECTS: Concurrent use of nadofaragene firadenovec in patients receiving immunosuppressive therapy may cause disseminated adenovirus infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Individuals who are immunosuppressed or immune-deficient should not receive nadofaragene firadenovec.(1) DISCUSSION: Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy but may contain low levels of replication-competent adenovirus. Immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection.(1)	ADSTILADRIN

There are 24 severe interactions. These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.

Drug Interaction	Drug Names
Selected Anticholinesterase/Corticosteroids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The mechanism of this interaction is unknown. CLINICAL EFFECTS: Concurrent use of these agents may contribute to increased muscle weakness and decreased response to anticholinesterases shortly after onset of corticosteroid therapy in the treatment of myasthenia gravis. Deterioration in muscle strength, including severe muscular depression, has been documented in patients with myasthenia gravis while receiving corticosteroids and anticholinesterases. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If possible, hold anticholinesterase agents at least 24 hours before initiating corticosteroid therapy. If concurrent use is necessary, close observation of the patient is indicated and life support systems should be available. DISCUSSION: Decreased effectiveness of anticholinesterases during the period of corticosteroid-induced increased weakness probably reflects a temporary increase in the severity of the disease process itself rather than a specific, direct interaction between the two drugs. Despite the initial adverse effect, glucocorticoid (or ACTH) therapy subsequently produces improvement, beyond pre-therapy muscle strength, in most myasthenia gravis patients. In an uncontrolled study involving nine patients receiving therapeutic doses of pyridostigmine, the concurrent administration of methylprednisolone resulted in a decrease in muscle strength in 71% of treatment courses. During 57% of treatment courses, severe muscle weakness occurred, necessitating mechanical ventilation. Improvement in muscle strength and response to pyridostigmine above baseline levels occurred after methylprednisolone was discontinued. Other clinical observations have indicated that the concomitant use of these agents can affect muscle strength, although each agent alone has been used successfully in treating myasthenia gravis.	ANTICHOLIUM, BLOXIVERZ, DEMECARIUM BROMIDE, EDROPHONIUM CHLORIDE, MESTINON, NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE-STERILE WATER, PREVDUO, PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE ER, REGONOL
Mifepristone/Corticosteroids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Mifepristone is an antagonist of the progesterone and glucocorticoid (GR-II) receptors, but has little effect at the mineralocorticoid (GR-I) receptor. Mifepristone has a higher affinity for the glucocorticoid receptor than either dexamethasone or cortisol and will displace both endogenous and exogenous glucocorticoids from their binding sites. CLINICAL EFFECTS: Although serum cortisol levels rise, antagonism of the glucocorticoid receptor may lead to adrenal insufficiency. Efficacy of locally administered corticosteroids may be diminished. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturers of mifepristone states that mifepristone is contraindicated in patients receiving concurrent long-term corticosteroid therapy.(1-2) Due to its long mean half-life of 85 hours(2), even short term mifepristone use may have an extended duration of effect. DISCUSSION: The manufacturers of mifepristone states that mifepristone is contraindicated in patients receiving concurrent long-term corticosteroid therapy.(1-2)	KORLYM, MIFEPREX, MIFEPRISTONE
Aldesleukin/Glucocorticoids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Corticosteroids may suppress interleukin-2-induced tumor necrosis factor (TNF) synthesis.(1) CLINICAL EFFECTS: Concurrent use of corticosteroids may reduce the antitumor effectiveness of aldesleukin.(2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of aldesleukin states that concurrent administration of corticosteroids and aldesleukin should be avoided.(2) DISCUSSION: Corticosteroids have been shown to reduce aldesleukin-related side effects such as fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea.(1,2) However, dexamethasone has been shown to reduce aldesleukin-induced TNF synthesis.(1)	PROLEUKIN
Selected Steroids/Antiretroviral CYP3A4 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Antiretroviral CYP3A4 inhibitors may inhibit the metabolism of corticosteroids metabolized by CYP3A4. Dexamethasone may induce metabolism of agents that are substrates of CYP3A4.(1-13,50) CLINICAL EFFECTS: Concurrent use of antiretroviral CYP3A4 inhibitors may result in increased systemic exposure to and effects from corticosteroids metabolized by CYP3A4, including Cushing's syndrome and adrenal suppression. Concurrent dexamethasone may result in decreased levels and effectiveness of CYP3A4 substrates. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If possible, avoid concurrent therapy of betamethasone, budesonide, ciclesonide, fluticasone, dexamethasone, methylprednisolone, or triamcinolone with antiretroviral CYP3A4 inhibitors. Alternative corticosteroids that are less affected by CYP3A4 inhibitors should be considered, like beclomethasone, prednisone, and prednisolone. If concurrent therapy is warranted, patients should be closely monitored for systemic effects. The corticosteroid may need to be discontinued. Patients receiving concurrent therapy with dexamethasone and substrates of CYP3A4 should also be monitored for decreased effectiveness of the CYP3A4 substrate. The manufacturers of nasal fluticasone(14-16) and fluticasone for inhalation(17) state that concurrent use of fluticasone and atazanavir, indinavir, nelfinavir, ritonavir or saquinavir is not recommended. The US manufacturers of atazanavir,(1) fosamprenavir,(5) indinavir(6) and nelfinavir(8) recommend caution with concurrent use of inhaled or nasal fluticasone. Consider alternatives to fluticasone if long-term use is required. DISCUSSION: In a study, boceprevir (800 mg TID for 7 days) increased the area-under-curve (AUC) of a single dose of prednisone (40 mg) by 22%. The maximum concentration (Cmax) and AUC of prednisolone increased by 16% and 37%, respectively.(2) A study of 14 healthy adults found that concurrent use of ketoconazole with ciclesonide increased the AUC of ciclesonide's active metabolite, des-ciclesonide, by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. However, the study concluded that no dosage adjustments were required because ciclesonide has a very low potential to cause side effects.(18) A study in 18 healthy subjects examined the effects of ritonavir (100 mg twice daily) on fluticasone nasal spray (200 mcg daily). In most subjects, fluticasone was undetectable (<10 pg/ml) when administered alone. In subjects in whom fluticasone was detectable when given alone, Cmax and area-under-curve AUC averaged 11.9 pg/ml and 8.43 pg x hr/ml, respectively. With concurrent ritonavir, fluticasone Cmax and AUC increased to 318 pg/ml and 3102.6 pg x hr/ml, respectively.(7,11,14) This reflects increases in Cmax and AUC by 25-fold and 350-fold, respectively.(3) The cortisol AUC decreased by 86%.(6,14-16) In a study in 10 healthy subjects, ritonavir (200 mg twice daily for 4 and 14 days) increased the AUC of a single dose of prednisolone by 1.41-fold and 1.30-fold, respectively, after 4 days and 14 days of ritonavir.(19) There have been several case reports of Cushing's syndrome in patients treated concurrently with ritonavir and inhaled budesonide,(19-20) dexamethasone,(22) injectable triamcinolone,(23-26) nasal fluticasone.(28-46) Hepatitis has also been reported with concurrent budesonide and ritonavir.(47) In a study in 9 healthy subjects, mibefradil (50 mg once daily for 3 days) increased the AUC, Cmax, and elimination half-life of methylprednisolone by 3.8-fold, 1.8-fold, and 2.7-fold, respectively.(48) In a study in 8 healthy subjects, following nefazodone administration the following changes were seen with methylprednisolone: mean (+/-SD) area under the concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).(49) Selected steroids linked to this monograph include: betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, and triamcinolone.(50) Selected CYP3A4 inhibitors and substrates linked to this monograph include: atazanavir, cobicistat, darunavir, fosamprenavir, indinavir, lenacapavir, lopinavir, nelfinavir, saquinavir, and tipranavir.(50)	APTIVUS, ATAZANAVIR SULFATE, DARUNAVIR, EVOTAZ, FOSAMPRENAVIR CALCIUM, GENVOYA, KALETRA, LOPINAVIR-RITONAVIR, PREZCOBIX, PREZISTA, REYATAZ, STRIBILD, SUNLENCA, SYMTUZA, TYBOST, VIRACEPT
Systemic Corticosteroids; Corticotropin (ACTH)/Live Vaccines SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Corticosteroids and corticotropin suppress the immune system. In severely immunocompromised patients, virus replication after administration of live, attenuated-virus vaccines can be enhanced and/or the immune response to the vaccine may be decreased.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) PREDISPOSING FACTORS: Patients receiving immunosuppressive doses of corticosteroids or corticotropin for equal to or greater than 14 consecutive days.(1) PATIENT MANAGEMENT: The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are severely immunosuppressed, including those who are receiving or have received high-dose, systemic steroids for greater than or equal to 14 consecutive days. Live vaccines should be deferred for at least 1 month after discontinuation of high-dose systemic steroids administered for 14 consecutive days. When initiating immunosuppressives doses of corticosteroids, wait 4 weeks after a live vaccines is administered. However, if patients require therapy for chronic inflammatory conditions, do not delay therapy due to past vaccines. Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued.(1) The US manufacturer of corticotropin(2) and triamcinolone(3) and the Australian manufacturer of dexamethasone(4) state that administration of live or live-attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids or corticotropin. The manufacturer of deflazacort states that live or live-attenuated vaccines should be administered at least 4 to 6 weeks prior to initiation of therapy with deflazacort.(5) DISCUSSION: Many clinicians consider a dose equivalent to either 2 mg/kg of body weight or a total of 20 mg/day of prednisone as sufficiently immunosuppressive to raise safety concerns about live-virus vaccines.(1) Immunization procedures may be undertaken in patients receiving corticosteroids when the therapy is short term (less than 2 weeks); low to moderate dose; long-term, alternate-day treatment with short-acting preparations; maintenance physiologic doses (replacement therapy); or administered topically (skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection.(1) Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1)	ACAM2000 (NATIONAL STOCKPILE), ADENOVIRUS TYPE 4, ADENOVIRUS TYPE 4 AND TYPE 7, ADENOVIRUS TYPE 7, BCG (TICE STRAIN), BCG VACCINE (TICE STRAIN), DENGVAXIA, ERVEBO (NATIONAL STOCKPILE), FLUMIST TRIVALENT 2024-2025, IXCHIQ, M-M-R II VACCINE, PRIORIX, PROQUAD, ROTARIX, ROTATEQ, STAMARIL, VARIVAX VACCINE, VAXCHORA ACTIVE COMPONENT, VAXCHORA VACCINE, VIVOTIF, YF-VAX
Amphotericin B/Corticosteroids; Corticotropin (ACTH) SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Corticosteroids and corticotropin may potentiate potassium excretion and overload salt and water retention.(1) CLINICAL EFFECTS: Concurrent use of amphotericin b with corticosteroids or corticotropin may potentiate amphotericin b-induced hypokalemia, thereby predisposing patients to cardiac dysfunction.(1-2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of amphotericin b states that concurrent use of corticosteroids or corticotropin should be avoided unless absolutely necessary to avoid side effects. If concurrent use is necessary, serum electrolytes and cardiac function must be monitored closely.(1) DISCUSSION: There are four case reports of cardiac enlargement, hypokalemia, and hypernatremia from concurrent use of amphotericin b and corticosteroids.(2)	ABELCET, AMBISOME, AMPHOTERICIN B, AMPHOTERICIN B LIPOSOME
Radioactive Iodide/Agents that Affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics.(1) CLINICAL EFFECTS: Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1) Because indocyanine green contains sodium iodide, the iodine-binding capacity of thyroid tissue may be reduced for at least one week following administration. Do not perform radioactive iodine uptake studies for at least one week following administration of indocyanine green.(2) The manufacturer of iopamidol states administration may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post administration of iopamidol.(3) DISCUSSION: Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1)	ADREVIEW, JEANATOPE, MEGATOPE, SODIUM IODIDE I-123
Tofacitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of tofacitinib and azathioprine, other biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants may result in additive or synergistic effects on the immune system.(1) CLINICAL EFFECTS: Concurrent use of tofacitinib and azathioprine, other biologic DMARDs, or potent immunosuppressants use may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Tofacitinib should not be used concurrently with azathioprine, other biologic DMARDs, or cyclosporine.(1) Patient should be monitored for decreases in lymphocytes and neutrophils. Therapy should be adjusted based on the indication. - For all indications: If absolute neutrophil count (ANC) or lymphocyte count is less than 500 cells/mm3, discontinue tofacitinib. - For rheumatoid arthritis or psoriatic arthritis and absolute neutrophil count (ANC) 500 to 1000 cells/mm3: interrupt dosing. When ANC is greater than 1000 cells/mm3, resume Xeljanz 5 mg twice daily or Xeljanz XR 11 mg once daily. - For ulcerative colitis and ANC 500 to 1000 cells/mm3: -If taking Xeljanz 10 mg twice daily, decrease to 5 mg twice daily. When ANC is greater than 1000 cells/mm3, increase to 10 mg twice daily based on clinical response. -If taking Xeljanz 5 mg twice daily, interrupt dosing. When ANC is greater than 1000 cells/mm3, resume 5 mg twice daily. -If taking Xeljanz XR 22 mg once daily, decrease to 11 mg once daily. When ANC is greater than 1000 cells/mm3, increase to 22 mg once daily based on clinical response. -If taking Xeljanz XR 11 mg once daily, interrupt dosing. When ANC is greater than 1000 cells/mm3, resume 11 mg once daily. - For polyarticular course juvenile idiopathic arthritis (pcJIA) and ANC 500 to 1000 cells/mm3: interrupt dosing until ANC is greater than 1000 cells/mm3.(1) DISCUSSION: Concurrent use of tofacitinib and azathioprine, other biologic DMARDs, or potent immunosuppressants may increase the risk of infection.(1)	TOFACITINIB CITRATE, XELJANZ, XELJANZ XR
Selected Multiple Sclerosis Agents/Immunosuppressants; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ocrelizumab or ofatumumab in combination with immunosuppressives and immune-modulators all suppress the immune system.(1,2) CLINICAL EFFECTS: Concurrent use of ocrelizumab or ofatumumab with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1,2) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ocrelizumab US prescribing information states: - Ocrelizumab and other immune-modulating or immunosuppressive therapies, (including immunosuppressant doses of corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with ocrelizumab. When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating ocrelizumab.(1) The ofatumumab US prescribing information states: - Ofatumumab and other immunosuppressive therapies (including systemic corticosteroids) may have the potential for increased immunosuppressive effects and increase the risk of infection. When switching between therapies, the duration and mechanism of action of each therapy should be considered due to the potential for additive immunosuppressive effects. Ofatumumab for MS therapy has not been studied in combination with other MS agents that suppress the immune system.(2) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1,2) In a retrospective cohort study of multiple sclerosis patients newly initiated on a disease-modifying therapy, use of high-efficacy agents (alemtuzumab, natalizumab, or ocrelizumab) resulted in the same risk of overall infections as moderate-efficacy agents, but there was an elevated risk of serious infections (adjusted hazard ratio [aHR] = 1.24, 95% confidence interval (CI) = 1.06-1.44) and UTIs (aHR = 1.21, 95% CI = 1.14-1.30).(3)	KESIMPTA PEN, OCREVUS, OCREVUS ZUNOVO
T Cell Immunotherapies/Corticosteroids SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Corticosteroids suppress the immune system. Concurrent use or premedication with a prophylactic corticosteroid may interfere with the activity of CAR-T cell immunotherapies.(1-6) CLINICAL EFFECTS: Corticosteroids may decrease the efficacy of CAR-T cell immunotherapies.(1-6) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturers recommend avoiding concurrent or prophylactic use of corticosteroids as a premedication prior to infusion of CAR-T cell immunotherapy. Corticosteroids may be used and are recommended in the case of a life-threatening emergency, including the management of cytokine release syndrome or neurological toxicities.(1-6) DISCUSSION: Corticosteroids may decrease the efficacy of CAR-T cell immunotherapy.(1-6) The manufacturers recommend avoiding concurrent or prophylactic use of corticosteroids as a premedication prior to infusion of CAR-T cell immunotherapy.(1-6) Corticosteroids may be used and are recommended in the case of a life-threatening emergency, including the management of cytokine release syndrome or neurological toxicities.(1-6)	ABECMA, AMTAGVI, AUCATZYL, BREYANZI, BREYANZI CD4 COMPONENT, BREYANZI CD8 COMPONENT, CARVYKTI, KYMRIAH, TECARTUS, TECELRA, YESCARTA
Cosyntropin/Agents Affecting Plasma Cortisol Levels SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Agents affecting plasma cortisol levels may impact the accuracy of the cosyntropin diagnostic test.(1) CLINICAL EFFECTS: Concurrent use of agents affecting plasma cortisol levels may impact the accuracy of the cosyntropin diagnostic test.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of cosyntropin states accuracy of diagnosis using the cosyntropin diagnostic test may be complicated by concomitant medications affecting plasma cortisol levels.(1) Agents affecting plasma cortisol levels and recommendation to stop prior to cosyntropin diagnostic test include: - Glucocorticoids: May elevate plasma cortisol levels. Stop these drugs on the day of testing. Long-acting glucocorticoids may need to be stopped for a longer period before testing. - Spironolactone: May elevate plasma cortisol levels. Stop spironolactone on the day of testing. - Estrogen: May elevate plasma total cortisol levels. Discontinue estrogen containing drugs 4 to 6 weeks prior to testing to allow cortisol binding globulin levels to return to levels within the reference range. Alternatively, concomitant measurement of cortisol binding globulin at the time of testing can be done; if cortisol binding globulin levels are elevated, plasma total cortisol levels are considered inaccurate.(1) DISCUSSION: Concurrent use of agents affecting plasma cortisol levels may impact the accuracy of the cosyntropin diagnostic test.(1)	CORTROSYN, COSYNTROPIN
Upadacitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Upadacitinib, immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of upadacitinib with immunosuppressives or immunomodulators may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of upadacitinib states that concurrent use of upadacitinib with immunosuppressives or immunomodulators is not recommended. DISCUSSION: Serious infections have been reported in patients receiving upadacitinib. Reported infections included pneumonia, cellulitis, tuberculosis, multidermatomal herpes zoster, oral/esophageal candidiasis, cryptococcosis. Reports of viral reactivation, including herpes virus reactivation and hepatitis B reactivation, were reported in clinical studies with upadacitinib.(1)	RINVOQ, RINVOQ LQ
Inebilizumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inebilizumab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of inebilizumab with immunosuppressive or immunomodulating agents may result in myelosuppression including neutropenia resulting in an increased risk for serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of inebilizumab states that the concurrent use of inebilizumab with immunosuppressive agents, including systemic corticosteroids, may increase the risk of infection. If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents.(1) DISCUSSION: Inebilizumab has not been studied in combination with other immunosuppressants. If concurrent therapy is warranted, consider the potential for increased immunosuppressive risks from both agents. The most common infections reported by inebilizumab treated patients in the randomized and open-label clinical trial periods included urinary tract infections (20%), nasopharyngitis (13%), upper respiratory tract infections (8%), and influenza (7%). Although there been no cases of Hepatitis B virus reactivation or progressive multifocal leukoencephalopathy reported in patients taking inebilizumab, these infections have been observed in patients taking other B-cell-depleting antibodies.(1)	UPLIZNA
Baricitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of baricitinib with other biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants such as azathioprine or cyclosporine may result in additive or synergistic effects on the immune system. CLINICAL EFFECTS: Concurrent use of baricitinib with other biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of baricitinib states that concurrent use of baricitinib with biologic DMARDs or potent immunosuppressants is not recommended.(1) DISCUSSION: Most patients who developed serious infections while being treated with baricitinib were on concomitant immunosuppressants like methotrexate and corticosteroids. The combination of baricitinib with other biologic DMARDs has not been studied.(1)	OLUMIANT
Ponesimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ponesimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ponesimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ponesimod US prescribing information states ponesimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ponesimod after alemtuzumab is not recommended. However, ponesimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1)	PONVORY
Fingolimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fingolimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-3) CLINICAL EFFECTS: Concurrent use of fingolimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1-3) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for fingolimod regarding this interaction differ between regulatory approving agencies. The fingolimod US prescribing information states: - Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with fingolimod. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating fingolimod.(1) The fingolimod Canadian prescribing information states: - Concurrent use with immunosuppressive or immunomodulatory agents is contraindicated due to the risk of additive immune system effects. However, co-administration of a short course of corticosteroids (up to 5 days) did not increase the overall rate of infection in patients participating Phase III clinical trials.(2) The fingolimod UK specific product characteristics states: - Fingolimod is contraindicated in patients currently receiving immunosuppressive therapies or those immunocompromised by prior therapies. When switching patients from another disease modifying therapy to Gilenya, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimizing the risk of disease activation.(3) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1-3)	FINGOLIMOD, GILENYA, TASCENSO ODT
Ozanimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ozanimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ozanimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ozanimod US prescribing information state this information regarding this interaction: -Ozanimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ozanimod after alemtuzumab is not recommended. However, ozanimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1)	ZEPOSIA
Siponimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Siponimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of siponimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The siponimod US prescribing information state this information regarding this interaction: -Siponimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with siponimod after alemtuzumab is not recommended. However, siponimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1)	MAYZENT
Cladribine/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Cladribine in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-2) CLINICAL EFFECTS: Concurrent use of cladribine with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1-2) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for cladribine regarding this interaction differ between regulatory approving agencies. The cladribine US prescribing information states: -Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine.(1) The cladribine Canadian prescribing information states: -Use of cladribine in immunocompromised patients is contraindicated because of a risk of additive effects on the immune system. Acute short-term therapy with corticosteroids can be administered during cladribine treatment.(2) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1-2)	CLADRIBINE, MAVENCLAD
Selected Steroids/Selected Strong CYP3A4 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Strong CYP3A4 inhibitors may inhibit the metabolism of corticosteroids metabolized by CYP3A4. CLINICAL EFFECTS: Concurrent use of strong CYP3A4 inhibitors may result in increased systemic exposure to and effects from corticosteroids metabolized by CYP3A4, including Cushing's syndrome and adrenal suppression. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If possible, avoid concurrent therapy between betamethasone, budesonide, ciclesonide, fluticasone, dexamethasone, methylprednisolone, or triamcinolone and strong CYP3A4 inhibitors. Alternative corticosteroids that are less affected by CYP3A4 inhibitors should be considered, like beclomethasone, prednisone, and prednisolone. If concurrent therapy is warranted, patients should be closely monitored for systemic effects. The corticosteroid may need to be discontinued. DISCUSSION: In a study, boceprevir (800 mg TID for 7 days) increased the area-under-curve (AUC) of a single dose of prednisone (40 mg) by 22%. The maximum concentration (Cmax) and AUC of prednisolone increased by 16% and 37%, respectively.(3) A study of 14 healthy adults found that concurrent use of ketoconazole with ciclesonide increased the AUC of ciclesonide's active metabolite, des-ciclesonide, by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged. However, the study concluded that no dosage adjustments were required because ciclesonide has a very low potential to cause side effects.(4) A study in 18 healthy subjects examined the effects of ritonavir (100 mg twice daily) on fluticasone nasal spray (200 mcg daily). In most subjects, fluticasone was undetectable (<10 pg/ml) when administered alone. In subjects in whom fluticasone was detectable when given alone, Cmax and area-under-curve AUC averaged 11.9 pg/ml and 8.43 pg x hr/ml, respectively. With concurrent ritonavir, fluticasone Cmax and AUC increased to 318 pg/ml and 3102.6 pg x hr/ml, respectively.(6-8) This reflects increases in Cmax and AUC by 25-fold and 350-fold, respectively.(6) The cortisol AUC decreased by 86%.(10-13) In a study in 10 healthy subjects, ritonavir (200 mg twice daily for 4 and 14 days) increased the AUC of a single dose of prednisolone by 1.41-fold and 1.30-fold, respectively, after 4 days and 14 days of ritonavir.(14) There have been several case reports of Cushing's syndrome in patients treated concurrently with ritonavir and inhaled budesonide,(15-16) dexamethasone,(17) injectable triamcinolone,(18-21) nasal fluticasone.(23-41) Hepatitis has also been reported with concurrent budesonide and ritonavir.(42) In a study in 9 healthy subjects, mibefradil (50 mg once daily for 3 days) increased the AUC, Cmax, and elimination half-life of methylprednisolone by 3.8-fold, 1.8-fold, and 2.7-fold, respectively.(43) In a study in 8 healthy subjects, following nefazodone administration the following changes were seen with methylprednisolone: mean (+/-SD) area under the concentration-time curve was significantly higher (1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P < 0.005), apparent clearance was lower (28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P < 0.02) and the terminal elimination half-life was longer (2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P < 0.02).(44) Selected steroids linked to this monograph include: betamethasone, budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, and triamcinolone.(45) Selected CYP3A4 inhibitors linked to this monograph include: adagrasib, boceprevir, ceritinib, lonafarnib, mibefradil, nefazodone, ribociclib, paritaprevir, telaprevir, and tucatinib.(1-2,45)	KISQALI, KRAZATI, NEFAZODONE HCL, TUKYSA, ZOKINVY, ZYKADIA
Ritlecitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ritlecitinib, immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of ritlecitinib with immunosuppressives or immunomodulators may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of ritlecitinib states that concurrent use of ritlecitinib with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants is not recommended.(1) DISCUSSION: Serious infections have been reported in patients receiving ritlecitinib. Reported infections included appendicitis, COVID-19 infection (including pneumonia), and sepsis. Reports of viral reactivation, including herpes virus reactivation was reported in clinical studies with ritlecitinib.(1)	LITFULO
Etrasimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Etrasimod causes reversible sequestration of lymphocytes in lymphoid tissues, resulting in a mean 55% decrease in peripheral blood lymphocyte count at 52 weeks.(1) Other immunosuppressives and immune-modulators also suppress the immune system. CLINICAL EFFECTS: Concurrent use of etrasimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious and fatal infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications increases the risk of adverse effects. PATIENT MANAGEMENT: The etrasimod US prescribing information states etrasimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Concomitant administration of these therapies with etrasimod should be avoided because of the risk of additive immune effects during therapy and in the weeks following administration. Etrasimod's effect on peripheral lymphocytes may persist for up to 5 weeks after discontinuation.(1) When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with other sphingosine-1 phosphate receptor modulators.(1)	VELSIPITY
Ropeginterferon alfa-2b/Slt Immunosuppress; Immunomodulator SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ropeginterferon alfa-2b and immunosuppressives both suppress the immune system. CLINICAL EFFECTS: Concurrent use of ropeginterferon alfa-2b with immunosuppressives may result in an increased risk of serious infections. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid concurrent use of myelosuppressive agents.(1-2) If concurrent use cannot be avoided, monitor for effects of excessive immunosuppression. DISCUSSION: In clinical trials, 20% of patients experienced leukopenia. Interferon alfa products may cause fatal or life-threatening infections.(1-2)	BESREMI
Sodium Iodide I 131/Myelosuppressives that affect Iodide SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) Many compounds can affect iodide protein binding and alter iodide pharmacokinetics and pharmacodynamics. CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) Compounds that affect iodide pharmacokinetics and pharmacodynamics may impact the effectiveness of radioactive iodide.(1,2) PREDISPOSING FACTORS: Compounds that affect iodide pharmacokinetics and pharmacodynamics are expected to have the most impact during therapy using radioactive iodide. Diagnostic procedures would be expected to be impacted less. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) Discuss the use of agents that affect iodide pharmacokinetics and pharmacodynamics with the patient's oncologist.(1,2) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) Many agents interact with radioactive iodine. The average duration of effect is: anticoagulants - 1 week antihistamines - 1 week anti-thyroid drugs, e.g: carbimazole, methimazole, propylthiouracil - 3-5 days corticosteroids - 1 week iodide-containing medications, e.g: amiodarone - 1-6 months expectorants - 2 weeks Lugol solution - 3 weeks saturated solution of potassium iodine - 3 weeks vitamins - 10-14 days iodide-containing X-ray contrast agents - up to 1 year lithium - 4 weeks phenylbutazone - 1-2 weeks sulfonamides - 1 week thyroid hormones (natural or synthetic), e.g.: thyroxine - 4 weeks tri-iodothyronine - 2 weeks tolbutamide - 1 week topical iodide - 1-9 months (1,2)	HICON, SODIUM IODIDE I-131

There are 15 moderate interactions. The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.

Drug Interaction	Drug Names
Corticosteroids/Hormonal Contraceptives; Estrogens SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: It is speculated that hormonal contraceptives and estrogens inhibit hepatic metabolism of some corticosteroids as well as endogenous cortisol. Competitive protein binding may also contribute to elevations in serum corticosteroids. CLINICAL EFFECTS: Concurrent use of hormonal contraceptives or estrogens may result in an increase in the therapeutic and toxic effects of corticosteroids. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients receiving concurrent hormonal contraceptives or estrogen should be observed for symptoms of corticosteroid toxicity. A lower corticosteroid dose may be required. DISCUSSION: In a study in 6 healthy females controlled on long-term oral contraceptives, subjects received either a placebo or high and low-dose prednisolone (0.53 and 0.14 mg/Kg iv). Both dosages of prednisolone decreased the total clearance, unbound clearance, and volume of distribution (Vd) at maximum concentration (Cmax) of total drug. Significant increases in half-life for free and unbound prednisolone and hydrocortisone concentrations were also observed in comparison to the placebo group. In a study in 8 females controlled on oral contraceptive therapy, 8 females not receiving contraceptive therapy, and 8 males, each subject received prednisolone 40 mg iv. The plasma clearance of total prednisolone in females on OC was 96 ml/min, which was significantly lower than those in both the male and female (205 and 187 ml/min, respectively) control groups. Prednisolone half-life and mean residence times were increased. The oral contraceptive group had a significantly higher (2-fold) concentration of transcortin, resulting in lower clearance, decreased Vd, and a 2-fold increase in the area-under-curve (AUC) for prednisolone. A clinical trial demonstrated the interaction between prednisolone (20 mg) and oral contraceptives containing ethinyl estradiol (30 mcg). The oral contraceptive users had an average plasma concentration of prednisolone 131% higher compared to the control group, and plasma cortisol levels were suppressed by approximately 90%. No differences were reported for ethinyl estradiol levels. In a study in 8 females taking oral contraceptives and 8 females who were were not, subjects received IV doses of prednisolone at 0.1 mg/Kg and 1.0 mg/Kg. Free prednisolone clearance was reduced by approximately 30% in the contraceptive receiving subjects compared to the control group, and plasma cortisol concentrations were reduced 2-fold compared to the control group. One or more of the drug pairs linked to this monograph have been included in a list of interactions that could be considered for classification as "non-interruptive" in EHR systems. This DDI subset was vetted by an expert panel commissioned by the U.S. Office of the National Coordinator (ONC) for Health Information Technology.	2-METHOXYESTRADIOL, ACTIVELLA, AFIRMELLE, ALTAVERA, ALYACEN, AMETHIA, AMETHYST, ANGELIQ, ANNOVERA, APRI, ARANELLE, ASHLYNA, AUBRA, AUBRA EQ, AUROVELA, AUROVELA 24 FE, AUROVELA FE, AVIANE, AYUNA, AZURETTE, BALCOLTRA, BALZIVA, BEYAZ, BIJUVA, BLISOVI 24 FE, BLISOVI FE, BRIELLYN, CAMRESE, CAMRESE LO, CAZIANT, CHARLOTTE 24 FE, CHATEAL EQ, CLIMARA, CLIMARA PRO, COMBIPATCH, COVARYX, COVARYX H.S., CRYSELLE, CYRED, CYRED EQ, DASETTA, DAYSEE, DELESTROGEN, DEPO-ESTRADIOL, DESOGESTR-ETH ESTRAD ETH ESTRA, DIETHYLSTILBESTROL, DIVIGEL, DOLISHALE, DOTTI, DROSPIRENONE-ETH ESTRA-LEVOMEF, DROSPIRENONE-ETHINYL ESTRADIOL, DUAVEE, EEMT, EEMT H.S., ELESTRIN, ELINEST, ELURYNG, ENILLORING, ENPRESSE, ENSKYCE, ESTARYLLA, ESTRACE, ESTRADIOL, ESTRADIOL (ONCE WEEKLY), ESTRADIOL (TWICE WEEKLY), ESTRADIOL BENZOATE, ESTRADIOL CYPIONATE, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE MICRO, ESTRADIOL MICRONIZED, ESTRADIOL VALERATE, ESTRADIOL-NORETHINDRONE ACETAT, ESTRATEST F.S., ESTRATEST H.S., ESTRING, ESTRIOL, ESTRIOL MICRONIZED, ESTROGEL, ESTROGEN-METHYLTESTOSTERONE, ESTRONE, ETHINYL ESTRADIOL, ETHYNODIOL-ETHINYL ESTRADIOL, ETONOGESTREL-ETHINYL ESTRADIOL, EVAMIST, FALMINA, FEMLYV, FEMRING, FINZALA, FYAVOLV, GEMMILY, HAILEY, HAILEY 24 FE, HAILEY FE, HALOETTE, ICLEVIA, ISIBLOOM, JAIMIESS, JASMIEL, JINTELI, JOLESSA, JOYEAUX, JULEBER, JUNEL, JUNEL FE, JUNEL FE 24, KAITLIB FE, KALLIGA, KARIVA, KELNOR 1-35, KELNOR 1-50, KURVELO, LARIN, LARIN 24 FE, LARIN FE, LAYOLIS FE, LEENA, LESSINA, LEVONEST, LEVONORG-ETH ESTRAD ETH ESTRAD, LEVONORG-ETH ESTRAD-FE BISGLYC, LEVONORGESTREL-ETH ESTRADIOL, LEVORA-28, LO LOESTRIN FE, LO-ZUMANDIMINE, LOESTRIN, LOESTRIN FE, LOJAIMIESS, LORYNA, LOW-OGESTREL, LUTERA, LYLLANA, MARLISSA, MENEST, MENOSTAR, MERZEE, MIBELAS 24 FE, MICROGESTIN, MICROGESTIN FE, MILI, MIMVEY, MINIVELLE, MINZOYA, MONO-LINYAH, MYFEMBREE, NATAZIA, NECON, NEXTSTELLIS, NIKKI, NORELGESTROMIN-ETH ESTRADIOL, NORETHIN-ETH ESTRA-FERROUS FUM, NORETHINDRON-ETHINYL ESTRADIOL, NORETHINDRONE-E.ESTRADIOL-IRON, NORGESTIMATE-ETHINYL ESTRADIOL, NORTREL, NUVARING, NYLIA, OCELLA, ORIAHNN, ORTHO TRI-CYCLEN, ORTHO-NOVUM, PHILITH, PIMTREA, PORTIA, PREMARIN, PREMPHASE, PREMPRO, RECLIPSEN, RIVELSA, SAFYRAL, SETLAKIN, SIMLIYA, SIMPESSE, SLYND, SPRINTEC, SRONYX, SYEDA, TARINA 24 FE, TARINA FE, TARINA FE 1-20 EQ, TAYTULLA, TILIA FE, TRI-ESTARYLLA, TRI-LEGEST FE, TRI-LINYAH, TRI-LO-ESTARYLLA, TRI-LO-MARZIA, TRI-LO-MILI, TRI-LO-SPRINTEC, TRI-MILI, TRI-SPRINTEC, TRI-VYLIBRA, TRI-VYLIBRA LO, TRIVORA-28, TURQOZ, TWIRLA, TYBLUME, VAGIFEM, VELIVET, VESTURA, VIENVA, VIORELE, VIVELLE-DOT, VOLNEA, VYFEMLA, VYLIBRA, WERA, WYMZYA FE, XULANE, YASMIN 28, YAZ, YUVAFEM, ZAFEMY, ZARAH, ZOVIA 1-35, ZUMANDIMINE
Corticosteroids/Selected Strong CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Strong CYP3A4 inducers may induce the metabolism of corticosteroids. Corticosteroids may affect the metabolism of phenytoin. CLINICAL EFFECTS: Concurrent or recent use of strong CYP3A4 inducers may result in decreased levels and effectiveness of corticosteroids. Dexamethasone has been shown to increase and decrease phenytoin levels. PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Patients receiving concurrent therapy with a strong CYP3A4 inducer should be monitored for decreased effectiveness of their corticosteroid. Increased dosage of corticosteroid may be required during concurrent therapy and for several weeks after completing concurrent therapy. If concurrent therapy is discontinued, the dosage of the corticosteroid may need to be adjusted. Phenytoin levels should be closely monitored in patients receiving corticosteroids. The dosage of phenytoin may need to be adjusted if corticosteroids are initiated or discontinued. DISCUSSION: Carbamazepine has been shown to increase the metabolism of methylprednisolone, prednisolone, and prednisone, resulting in decreased levels and effectiveness of these agents. Phenobarbital has been shown to increase the metabolism of dexamethasone, methylprednisolone, and prednisolone. Primidone is metabolized to phenobarbital. Phenytoin has been shown to increase the metabolism of dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone, resulting in decreased levels and effectiveness of these agents Rifampin has been shown to increase the metabolism of cortisol, dexamethasone, methylprednisolone, prednisolone, and prednisone. Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, rifampin, and St. John's wort.	ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, BRAFTOVI, BUTALB-ACETAMINOPH-CAFF-CODEIN, BUTALBITAL, BUTALBITAL-ACETAMINOPHEN, BUTALBITAL-ACETAMINOPHEN-CAFFE, BUTALBITAL-ASPIRIN-CAFFEINE, CARBAMAZEPINE, CARBAMAZEPINE ER, CARBATROL, CEREBYX, DILANTIN, DILANTIN-125, DONNATAL, EPITOL, EQUETRO, ERLEADA, ESGIC, FIORICET, FIORICET WITH CODEINE, FOSPHENYTOIN SODIUM, LYSODREN, MITOTANE, MYSOLINE, ORKAMBI, PENTOBARBITAL SODIUM, PHENOBARBITAL, PHENOBARBITAL SODIUM, PHENOBARBITAL-BELLADONNA, PHENOBARBITAL-HYOSC-ATROP-SCOP, PHENOHYTRO, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED, PRIFTIN, PRIMIDONE, RIFABUTIN, RIFADIN, RIFAMPIN, SEZABY, TALICIA, TEGRETOL, TEGRETOL XR, TENCON, TIBSOVO, XTANDI
NSAIDs/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Concurrent use of NSAIDs and corticosteroids result in additive risk of GI ulceration. CLINICAL EFFECTS: Concurrent use of NSAIDs and corticosteroids may increase the incidence and/or severity of GI irritation or ulceration, including increasing the risk for bleeding. PREDISPOSING FACTORS: Risk of GI bleed may be increased in patients who are of older age, in poor health status, or who use alcohol or smoke. Risk may also be increased by concurrent use of anticoagulants, antiplatelets, selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs); with longer duration of NSAID use; and with prior history of peptic ulcer disease and/or GI bleeding. The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia, advanced liver disease). PATIENT MANAGEMENT: Monitor patients receiving concurrent therapy carefully for signs of gastrointestinal ulceration. Use the lowest effective NSAID dose for the shortest duration possible. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. Instruct patients to report signs of GI bleeding such as black, tarry stools; "coffee ground" vomit; nausea; or stomach/abdominal pain. DISCUSSION: Concurrent use of NSAIDs and corticosteroids increase the risk of GI bleeding.	ANAPROX DS, ANJESO, ARTHROTEC 50, ARTHROTEC 75, BROMFENAC SODIUM, BUPIVACAINE-KETOROLAC-KETAMINE, CALDOLOR, CAMBIA, CELEBREX, CELECOXIB, COMBOGESIC IV, CONSENSI, COXANTO, DAYPRO, DICLOFENAC, DICLOFENAC POTASSIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM ER, DICLOFENAC SODIUM MICRONIZED, DICLOFENAC SODIUM-MISOPROSTOL, EC-NAPROSYN, EC-NAPROXEN, ELYXYB, ETODOLAC, ETODOLAC ER, FELDENE, FENOPROFEN CALCIUM, FENOPRON, FLURBIPROFEN, HYDROCODONE-IBUPROFEN, IBU, IBUPAK, IBUPROFEN, IBUPROFEN LYSINE, IBUPROFEN-FAMOTIDINE, INDOCIN, INDOMETHACIN, INDOMETHACIN ER, INFLAMMACIN, INFLATHERM(DICLOFENAC-MENTHOL), KETOPROFEN, KETOPROFEN MICRONIZED, KETOROLAC TROMETHAMINE, KIPROFEN, LODINE, LOFENA, MECLOFENAMATE SODIUM, MEFENAMIC ACID, MELOXICAM, NABUMETONE, NABUMETONE MICRONIZED, NALFON, NAPRELAN, NAPROSYN, NAPROTIN, NAPROXEN, NAPROXEN SODIUM, NAPROXEN SODIUM CR, NAPROXEN SODIUM ER, NAPROXEN-ESOMEPRAZOLE MAG, NEOPROFEN, OXAPROZIN, PHENYLBUTAZONE, PIROXICAM, R.E.C.K.(ROPIV-EPI-CLON-KETOR), RELAFEN DS, ROPIVACAINE-CLONIDINE-KETOROLC, ROPIVACAINE-KETOROLAC-KETAMINE, SULINDAC, SUMATRIPTAN SUCC-NAPROXEN SOD, TOLECTIN 600, TOLMETIN SODIUM, TORONOVA II SUIK, TORONOVA SUIK, TOXICOLOGY SALIVA COLLECTION, TREXIMET, VIMOVO, VIVLODEX, ZIPSOR, ZORVOLEX
Salicylates/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unknown. However, it is speculated that renal and hepatic elimination of salicylates may be increased by corticosteroids. CLINICAL EFFECTS: Decreased serum salicylate levels with reduced therapeutic response. Salicylate intoxication may occur when corticosteroid dosage is decreased in patients taking large doses of salicylates. Gastrointestinal ulceration may be increased as well. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Adjust the salicylate dose as needed based on salicylate levels and patient response. Caution when discontinuing corticosteroids, as a decrease in salicylate dose may be needed to avoid salicylate toxicity. DISCUSSION: Additional documentation is necessary to confirm this potential interaction.	5-AMINOSALICYLIC ACID, ACETYL SALICYLIC ACID, APRISO, ASA-BUTALB-CAFFEINE-CODEINE, ASCOMP WITH CODEINE, ASPIRIN, ASPIRIN-DIPYRIDAMOLE ER, AZULFIDINE, BISMUTH SUBSALICYLATE, BUTALBITAL-ASPIRIN-CAFFEINE, CANASA, CARISOPRODOL-ASPIRIN, CARISOPRODOL-ASPIRIN-CODEINE, CHOLINE MAGNESIUM TRISALICYLAT, DELZICOL, DIFLUNISAL, DIPENTUM, DISALCID, DOLOBID, DURLAZA, LIALDA, MESALAMINE, MESALAMINE DR, MESALAMINE ER, NORGESIC, NORGESIC FORTE, ORPHENADRINE-ASPIRIN-CAFFEINE, ORPHENGESIC FORTE, PENTASA, PHENYL SALICYLATE, ROWASA, SALSALATE, SFROWASA, SODIUM SALICYLATE, SULFASALAZINE, SULFASALAZINE DR, URETRON D-S, URIBEL TABS, URIMAR-T, URNEVA, URO-MP, URO-SP, YOSPRALA
Corticosteroids/Selected Macrolide Antibiotics SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Some macrolide antibiotics may inhibit the metabolism of corticosteroids. CLINICAL EFFECTS: Concurrent use of some macrolide antibiotics may result in elevated levels and clinical effects of corticosteroids. Immunosuppression and Cushing's syndrome have been reported during concurrent therapy, including therapy with inhaled corticosteroids. PREDISPOSING FACTORS: Concurrent administration of enzyme inducing drugs. PATIENT MANAGEMENT: Patients receiving concurrent therapy with corticosteroids and macrolide antibiotics should be monitored for increased corticosteroid affects. The dosage of the corticosteroid may need to be adjusted or the macrolide antibiotic may need to be discontinued. One US manufacturer of inhaled fluticasone states that the concurrent use of macrolide antibiotics is not recommended.(1) DISCUSSION: In a study in 10 steroid-dependent asthmatics, concurrent troleandomycin (1 gram/day) decreased methylprednisolone clearance by 60%. All subjects developed adverse effects typical of excessive corticosteroid use such as weight gain, fluid retention, and cushingoid features.(2) Other studies and reports have shown increased methylprednisolone levels with concurrent troleandomycin,(3-10) in some of these reports, the interaction was used to lower steroid dosages.(6-10) There is one report of fatal varicella infection in a patient receiving concurrent therapy with methylprednisolone and troleandomycin.(11) Cushing's syndrome has been reported with concurrent inhaled budesonide and clarithromycin.(12) Psychosis(13) and mania(14) have been reported with concurrent prednisone and clarithromycin. Erythromycin(3-9) and troleandomycin(9) have also been reported to interact with methylprednisolone.	CLARITHROMYCIN, CLARITHROMYCIN ER, E.E.S. 200, E.E.S. 400, ERY-TAB, ERYPED 200, ERYPED 400, ERYTHROCIN LACTOBIONATE, ERYTHROCIN STEARATE, ERYTHROMYCIN, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN LACTOBIONATE, LANSOPRAZOL-AMOXICIL-CLARITHRO, OMECLAMOX-PAK, VOQUEZNA TRIPLE PAK
Anticoagulants/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Corticosteroids may increase the coagulability of blood, thus decreasing the effect of the anticoagulant.(1,2) Corticosteroids may also lower vascular integrity, which could increase the risk of hemorrhage.(3,4) CLINICAL EFFECTS: Concurrent use of corticosteroids may result in either increased (increased risk of bleeding) or decreased effects (increased risk of treatment failure) of anticoagulants. PREDISPOSING FACTORS: The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: The patient's clotting times should be monitored closely, along with any clinical signs of hemorrhage or clot formation. The dosage of the anticoagulant may need to be adjusted accordingly. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: Corticotropin and other corticosteroids have been shown to both increase (3,5-11) and decrease (1,12,13) the effects of acenocoumarol, dicumarol, fluindione, and warfarin. Hemorrhagic episodes have been associated with concurrent use of these medications.(3,5) One or more of the drug pairs linked to this monograph have been included in a list of interactions that could be considered for classification as "non-interruptive" in EHR systems. This DDI subset was vetted by an expert panel commissioned by the U.S. Office of the National Coordinator (ONC) for Health Information Technology.	ANISINDIONE, DICUMAROL, ELMIRON, JANTOVEN, PENTOSAN POLYSULFATE SODIUM, PHENINDIONE, WARFARIN SODIUM
Bupropion/Steroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Both bupropion and systemic steroids are known to lower the seizure threshold.(1,2) CLINICAL EFFECTS: Concurrent use of bupropion and systemic steroids may result in additive effects on the seizure threshold, increasing the risk of seizures.(1,2) PREDISPOSING FACTORS: The risk of seizures may be increased in patients with a history of head trauma or prior seizure; CNS tumor; severe hepatic cirrhosis; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants an anorectics; a total daily dose of bupropion greater than 450 mg or single doses greater than 150 mg; rapid escalation of bupropion dosage; diabetics treated with oral hypoglycemics or insulin; or with concomitant medications known to lower seizure threshold (antidepressants, antipsychotics, theophylline).(1,2) PATIENT MANAGEMENT: The concurrent use of bupropion and systemic steroids should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2) Single doses should not exceed 150 mg.(1,2) The maximum daily dose of bupropion should not exceed 300 mg for smoking cessation(2) or 450 mg for depression.(1) DISCUSSION: Because of the risk of seizure from concurrent bupropion and other agents that lower seizure threshold, the manufacturer of bupropion states that the concurrent use of bupropion and systemic steroids should be undertaken only with extreme caution and with low initial bupropion dosing and small gradual dosage increases.(1,2)	APLENZIN, AUVELITY, BUPROPION HCL, BUPROPION HCL SR, BUPROPION XL, CONTRAVE, FORFIVO XL, WELLBUTRIN SR, WELLBUTRIN XL
Quinolones/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Quinolone-induced arthropathy is a class effect of the quinolones.(1) Exactly how corticosteroid use increases the risk of tendon rupture is unknown. CLINICAL EFFECTS: Concurrent use of quinolones and corticosteroids may increase the risk of tendonitis and/or tendon rupture. This affect is most common in the Achilles tendon, but has been reported in the rotator cuff (shoulder), hand, biceps, thumb, and other tendons.(2-9) PREDISPOSING FACTORS: Risk factors for tendinitis and tendon rupture include age greater than 60; a history of kidney, heart, or lung transplantation, strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. PATIENT MANAGEMENT: Quinolone use should be discontinued if the patient experiences pain, inflammation, or rupture of a tendon. Patients should be instructed to rest and refrain from exercise until the diagnosis of tendonitis tendon rupture has been excluded.(2-9) DISCUSSION: Ruptures of the shoulder, hand, Achilles tendon, or other tendons that required surgical repair or resulted in prolonged disability have been reported in patients receiving ciprofloxacin,(2) gatifloxacin,(3) levofloxacin,(4) lomefloxacin,(5) moxifloxacin,(6) nalidixic acid,(7) norfloxacin,(8) and ofloxacin.(9) A retrospective review of the IMS Health database examined quinolone use use from July 1, 1992 to June 30, 1998. The adjusted relative risk of tendon disorder with concurrent quinolone use was 1.9. Relative risk increased to 3.2 in patients aged 60 or older compared to 0.9 in patients aged less than 60. In patients aged 60 or older who used corticosteroids and quinolones concurrently, relative risk increased to 6.2.(10) In contrast, another retrospective review examined patients from a health insurance claims database and found no apparent effect from concurrent quinolone and corticosteroid use.(11) In a review of the follow-up to 42 spontaneously reported case of quinolone-associated tendon disorders in the Netherlands between January, 1988 and January, 1998, risk factors for tendon disorders included age older than 60, oral corticosteroid use, and existing joint problems.(12) In a review of the Swiss Drug Monitoring system, four of seven cases of levofloxacin-associated tendon problems also involved concurrent oral or inhaled corticosteroids.(13) In a review of the Medline database from 1966-2001, 98 case reports of tendinopathy associated with quinolones were located. Thirty-two (32.7%) of the patients had received systemic or inhaled corticosteroids before and during quinolone therapy. Of the 40 patients who suffered a tendon rupture, 21 (52.5%) were receiving corticosteroids.(14) Other authors have reported cases of tendon disorders in patients receiving concurrent corticosteroids and ciprofloxacin,(15) levofloxacin, (16-20) and ofloxacin.(21)	AVELOX IV, BAXDELA, CIPRO, CIPROFLOXACIN, CIPROFLOXACIN HCL, CIPROFLOXACIN-D5W, GATIFLOXACIN SESQUIHYDRATE, LEVOFLOXACIN, LEVOFLOXACIN HEMIHYDRATE, LEVOFLOXACIN-D5W, MOXIFLOXACIN, MOXIFLOXACIN HCL, NALIDIXIC ACID, OFLOXACIN
Selected Corticosteroids/Selected Azole Antifungal Agents SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Itraconazole, ketoconazole, posaconazole, and voriconazole may inhibit the CYP3A4 mediated metabolism of some corticosteroids, resulting in increased systemic exposure. Itraconazole and ketoconazole may also suppress endogenous cortisol output. CLINICAL EFFECTS: Concurrent use of itraconazole, ketoconazole, posaconazole, or voriconazole may result in elevated levels of and effects from the corticosteroid, including Cushing syndrome. These effects have been seen with systemic as well as inhaled corticosteroids. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should be carefully monitored with concurrent administration of these agents, or when itraconazole, ketoconazole, posaconazole, or voriconazole is added to corticosteroid therapy. The dose of the corticosteroid may need to be adjusted or alternative therapy considered. DISCUSSION: In a randomized, double-blind, cross-over study in 10 healthy subjects, pretreatment with itraconazole (200 mg daily for 5 days) increased the area-under-curve (AUC) and maximum concentration (Cmax) of a single inhaled dose of budesonide (1000 mcg) by 4.2-fold and 1.6-fold, respectively. Suppression of cortisol production was increased 43%.(1) A study examined adrenal insufficiency in 25 cystic fibrosis patients treated with itraconazole and inhaled budesonide and in 12 patients receiving itraconazole alone. Eleven of the 25 patients receiving concurrent itraconazole and budesonide and none of the patients receiving only itraconazole had adrenal insufficiency.(2) There are case reports of Cushing syndrome in patients receiving concurrent itraconazole (range 200 mg to 800 mg daily) and inhaled budesonide (range 400 mcg to 1400 mcg daily).(3-5) The concurrent use of ketoconazole has been shown to increase budesonide area-under-curve (AUC) by eight-fold.(6) In a study in eight healthy subjects, the simultaneous administration of ketoconazole increased budesonide AUC by 6.5-fold. Administering the two agents 12 hours apart increased budesonide AUC by 3.8-fold.(7) There are case reports of Cushing syndrome in patients receiving concurrent itraconazole (range 100 mg to 400 mg daily) and inhaled fluticasone (range 250 mcg to 1.5 mg daily).(8,9) In a randomized, placebo-controlled, crossover, four phase study in 8 healthy subjects, itraconazole decreased the systemic clearance of intravenous dexamethasone by 68%, increased the area-under-curve (AUC) of dexamethasone by 3.3-fold, and prolonged its half-life by 3.2-fold. The AUC of oral dexamethasone was increased 3.7-fold, maximum concentration (Cmax) was increased by 1.7-fold, and the elimination half-life was prolonged 2.8-fold by itraconazole.(10) In a randomized, cross-over study in 14 healthy subjects, pretreatment with itraconazole (400 mg Day 1, 200 mg Days 2-4) increased the AUC of a single oral dose of methylprednisolone by 1.5-fold. Cortisol levels were significantly lower after concurrent therapy than with methylprednisolone alone.(11) There is a case report of Cushing syndrome following the addition of itraconazole (400 mg daily) to methylprednisolone (12 mg/day).(12) In a study in 6 healthy subjects, pretreatment with ketoconazole (200 mg daily) increased the AUC of a single intravenous dose of methylprednisolone (20 mg) by 135% and decreased its clearance by 60%. Concurrent ketoconazole also increased the reduction in 24-hour cortisol AUC and suppressed morning cortisol concentrations.(13) In a study in 8 healthy subjects, ketoconazole decreased the clearance of methylprednisolone by 46% and increased mean residence time by 37%.(14) In a randomized, cross-over study in 14 healthy subjects, pretreatment with itraconazole (400 mg Day 1, 200 mg Days 2-4) had no effect on the pharmacokinetics of a single oral dose of prednisone (60 mg).(11) In a randomized, cross-over study in 6 healthy subjects, pretreatment with ketoconazole (200 mg daily for 6 days) had no effect on the pharmacokinetics of a single intravenous dose of prednisolone (14.8 mg).(15) In a randomized, double-blind, cross-over study in 10 healthy subjects, pretreatment with itraconazole (200 mg daily for 4 days) increased the AUC and half-life of a single oral dose of prednisolone (20 mg) by 24% and 29%, respectively.(16) In a study, concurrent oral ketoconazole increased the AUC of des-ciclesonide from orally inhaled ciclesonide by 3.6-fold. There were no changes in ciclesonide levels.(17) In a study in 24 healthy subjects, subjects were randomized to receive either ketoconazole (200 mg BID) or placebo on Days 4-9 of a a 9 day course of mometasone (400 mcg BID). No subject had mometasone levels greater than 150 pcg/ml on Day 3. Four of 12 subjects who received ketoconazole had mometasone Cmax levels greater than 200 mcg/ml on Day 9. Plasma cortisol levels appeared to decrease as well.(18) In a cross-over study in 15 healthy subjects, subjects were randomized to receive fluticasone furoate and vilanterol on days 5-11 with either ketoconazole (200mg once daily) or placebo for days 1-11 with a washout period of 7-14 days. Fluticasone furoate AUC was increased by 36%, Cmax was increased by 33%, and decreased systemic cortisol levels by 27%. There were no effects on heart rate and blood potassium levels. There was a small increase in QTc which was 7.6ms greater when compared to placebo; however, ketoconazole has been reported to increase QTc by 5-6ms. Vilanterol AUC was increased by 65% and Cmax was increased by 22%. There were no effects on heart rate and blood potassium levels. No serious adverse events occurred and no subjects withdrew from the study due to adverse events. The most common adverse event reported was headache. (19) Coadministration of orally inhaled fluticasone (1000 mcg) and ketoconazole (200 mg once daily) resulted in a 1.9-fold increase in plasma fluticasone exposure and a 45% decrease in plasma cortisol AUC.(20) There is a case report of Cushing syndrome following the addition of voriconazole (200 mg twice daily for 21 days for 2 courses) to budesonide,(21) as well as voriconazole added to intranasal mometasone(22) and inhaled fluticasone.(22) There is a case report of Cushing syndrome following the addition of posaconazole (200 mg three times daily) to inhaled fluticasone.(23)	ITRACONAZOLE, ITRACONAZOLE MICRONIZED, KETOCONAZOLE, NOXAFIL, POSACONAZOLE, SPORANOX, TOLSURA, VFEND, VFEND IV, VORICONAZOLE
Erlotinib/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown. CLINICAL EFFECTS: Concurrent use of corticosteroids may increase the risk of gastrointestinal perforation in patients receiving erlotinib. Fatalities have been reported.(1) PREDISPOSING FACTORS: Patients with a history of peptic ulceration or diverticular disease or who are receiving concomitant anti-angiogenic, NSAIDs, and/or taxane-based chemotherapy may be an increased risk of gastrointestinal perforation.(1) PATIENT MANAGEMENT: Monitor patients receiving concurrent therapy for signs of gastrointestinal perforation. Discontinue erlotinib in patients who develop gastrointestinal perforation.(1) DISCUSSION: In a phase II trial of concurrent bevacizumab plus erlotinib, 2 of 13 patients suffered fatal gastrointestinal perforations.(2) In another phase II trial of concurrent bevacizumab with erlotinib, 1 of 104 patients died of gastrointestinal perforation.(3) Two patients developed gastrointestinal perforations while taking erlotinib, corticosteroids, and ciprofloxacin.(3)	ERLOTINIB HCL, TARCEVA
Gallium Ga 68 Dotatate/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: High-dose corticosteroids may down-regulate somatostatin subtype 2 receptors, the main binding site for gallium Ga 68 dotatate.(1) CLINICAL EFFECTS: Repeated use of high doses of corticosteroids before use of gallium Ga 68 dotatate may result in false negative imaging results.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: In patients receiving high-dose corticosteroids prior to use of gallium Ga 68 dotatate, interpret imaging results with caution and in the context of the patient's clinical presentation. DISCUSSION: Repeated use of high doses of corticosteroids before use of gallium Ga 68 dotatate may result in false negative imaging results due to down-regulation of the somatostatin subtype 2 receptor.(1)	GALLIUM GA-68 DOTATOC, NETSPOT
Selected Corticosteroids/Levoketoconazole SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Levoketoconazole may inhibit the CYP3A4 mediated metabolism of some corticosteroids, resulting in increased systemic exposure. Levoketoconazole may also suppress endogenous cortisol output. Levoketoconazole is the enantiomer of ketoconazole. CLINICAL EFFECTS: Concurrent use of levoketoconazole may result in elevated levels of and effects from the corticosteroid, including Cushing syndrome. These effects have been seen with systemic as well as inhaled corticosteroids. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should be carefully monitored with concurrent administration of these agents, or when levoketoconazole is added to corticosteroid therapy. The dose of the corticosteroid may need to be adjusted or alternative therapy considered. DISCUSSION: The concurrent use of ketoconazole has been shown to increase budesonide area-under-curve (AUC) by eight-fold. In a study in eight healthy subjects, the simultaneous administration of ketoconazole increased budesonide AUC by 6.5-fold. Administering the two agents 12 hours apart increased budesonide AUC by 3.8-fold. In a study in 6 healthy subjects, pretreatment with ketoconazole (200 mg daily) increased the AUC of a single intravenous dose of methylprednisolone (20 mg) by 135% and decreased its clearance by 60%. Concurrent ketoconazole also increased the reduction in 24-hour cortisol AUC and suppressed morning cortisol concentrations. In a study in 8 healthy subjects, ketoconazole decreased the clearance of methylprednisolone by 46% and increased mean residence time by 37%. In a randomized, cross-over study in 6 healthy subjects, pretreatment with ketoconazole (200 mg daily for 6 days) had no effect on the pharmacokinetics of a single intravenous dose of prednisolone (14.8 mg). In a study, concurrent oral ketoconazole increased the AUC of des-ciclesonide from orally inhaled ciclesonide by 3.6-fold. There were no changes in ciclesonide levels. In a study in 24 healthy subjects, subjects were randomized to receive either ketoconazole (200 mg BID) or placebo on Days 4-9 of a a 9 day course of mometasone (400 mcg BID). No subject had mometasone levels greater than 150 pcg/ml on Day 3. Four of 12 subjects who received ketoconazole had mometasone Cmax levels greater than 200 mcg/ml on Day 9. Plasma cortisol levels appeared to decrease as well. In a cross-over study in 15 healthy subjects, subjects were randomized to receive fluticasone furoate and vilanterol on days 5-11 with either ketoconazole (200mg once daily) or placebo for days 1-11 with a washout period of 7-14 days. Fluticasone furoate AUC was increased by 36%, Cmax was increased by 33%, and decreased systemic cortisol levels by 27%. There were no effects on heart rate and blood potassium levels. There was a small increase in QTc which was 7.6ms greater when compared to placebo; however, ketoconazole has been reported to increase QTc by 5-6ms. Vilanterol AUC was increased by 65% and Cmax was increased by 22%. There were no effects on heart rate and blood potassium levels. No serious adverse events occurred and no subjects withdrew from the study due to adverse events. The most common adverse event reported was headache. Coadministration of orally inhaled fluticasone (1000 mcg) and ketoconazole (200 mg once daily) resulted in a 1.9-fold increase in plasma fluticasone exposure and a 45% decrease in plasma cortisol AUC.	RECORLEV
Selected Steroids/Nirmatrelvir-Ritonavir SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Nirmatrelvir/ritonavir may inhibit the metabolism of corticosteroids metabolized by CYP3A4.(1) CLINICAL EFFECTS: Nirmatrelvir/ritonavir may result in increased systemic exposure to and effects from corticosteroids metabolized by CYP3A4.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Coadministration with corticosteroids of all routes of administration of which exposures are significantly increased by strong CYP3A4 inhibitors can increase the risk of Cushing's syndrome and adrenal suppression. However, the risk of Cushing's syndrome and adrenal suppression associated with short-term use of a strong CYP3A4 inhibitor is low.(1) The manufacturer of nirmatrelvir/ritonavir recommends considering alternative corticosteroids including beclomethasone, prednisone, and prednisolone.(1) DISCUSSION: Concurrent use of a single dose of midazolam 2 mg, a CYP3A4 substrate, with nirmatrelvir-ritonavir (300 mg/100 mg twice daily for nine doses) increased the maximum concentration (Cmax) and area-under-curve (AUC) of midazolam by 37% and 143%, respectively.(1) A study in 18 healthy subjects examined the effects of ritonavir (100 mg twice daily) on fluticasone nasal spray (200 mcg daily). In most subjects, fluticasone was undetectable (<10 pg/ml) when administered alone. In subjects in whom fluticasone was detectable when given alone, Cmax and area-under-curve AUC averaged 11.9 pg/ml and 8.43 pg x hr/ml, respectively. With concurrent ritonavir, fluticasone Cmax and AUC increased to 318 pg/ml and 3102.6 pg x hr/ml, respectively.(7,11,13) This reflects increases in Cmax and AUC by 25-fold and 350-fold, respectively.(3) The cortisol AUC decreased by 86%.(3-6) In a study in 10 healthy subjects, ritonavir (200 mg twice daily for 4 and 14 days) increased the AUC of a single dose of prednisolone by 1.41-fold and 1.30-fold, respectively, after 4 days and 14 days of ritonavir.(7) Selected steroids linked to this monograph include: budesonide, ciclesonide, dexamethasone, fluticasone, methylprednisolone, and triamcinolone.(8)	PAXLOVID
Systemic Corticosteroids; Corticotropin/Non-Live Vaccines SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Corticosteroids and corticotropin suppress the immune system and may alter the immune system's response to vaccines.(1) CLINICAL EFFECTS: Vaccines administered during or within 2 weeks prior to therapy with corticosteroids or corticotropin may result in decreased effectiveness of the vaccine.(1) PREDISPOSING FACTORS: Patients receiving immunosuppressive doses of corticosteroids or corticotropin for equal to or greater than 14 consecutive days.(1) PATIENT MANAGEMENT: The Centers for Disease Control's (CDC) Advisory Committee on Immunization Practices (ACIP) states that non-live vaccines should be used with caution in patients who are severely immunosuppressed, including those who are receiving or have received high-dose, systemic steroids for greater than or equal to 14 consecutive days. When initiating immunosuppressives doses of corticosteroids, wait 2 weeks after a non-live vaccines is administered. However, if patients require therapy for chronic inflammatory conditions, do not delay therapy due to past vaccines.(1) The immune response to non-live vaccines should be monitored in patients receiving corticosteroids. Vaccinations given during corticosteroid therapy may need to be repeated.(1) Patients who are vaccinated within the 14 days prior to initiating immunosuppressive therapy should be considered unvaccinated and should be revaccinated at least 3 months after immunosuppressive therapy is discontinued when immune competence is restored.(1) DISCUSSION: Vaccinations given during and within 2 weeks prior to corticosteroid therapy may be less effective. However they are considered safe to administer.(1) Many clinicians consider a dose equivalent to either 2 mg/kg of body weight or a total of 20 mg/day of prednisone as sufficiently immunosuppressive to raise safety concerns about live-virus vaccines.(1) Immunization procedures may be undertaken in patients receiving corticosteroids when the therapy is short term (less than 2 weeks); low to moderate dose; long-term, alternate-day treatment with short-acting preparations; maintenance physiologic doses (replacement therapy); or administered topically (skin or eyes), by aerosol, or by intra-articular, bursal, or tendon injection.(1)	ACTHIB, ADACEL TDAP, AREXVY, AREXVY ANTIGEN COMPONENT, BEXSERO, BIOTHRAX, BOOSTRIX TDAP, CAPVAXIVE, COMIRNATY 2024-2025, CYFENDUS (NATIONAL STOCKPILE), DAPTACEL DTAP, ENGERIX-B ADULT, ENGERIX-B PEDIATRIC-ADOLESCENT, GARDASIL 9, HAVRIX, HEPLISAV-B, HIBERIX, IMOVAX RABIES VACCINE, INFANRIX DTAP, IPOL, IXIARO, JYNNEOS, JYNNEOS (NATIONAL STOCKPILE), KINRIX, MENQUADFI, MENVEO A-C-Y-W-135-DIP, MENVEO MENA COMPONENT, MENVEO MENCYW-135 COMPONENT, MODERNA COVID 24-25(6M-11Y)EUA, MRESVIA, NOVAVAX COVID 2024-2025 (EUA), PEDIARIX, PEDVAXHIB, PENBRAYA, PENBRAYA MENACWY COMPONENT, PENBRAYA MENB COMPONENT, PENTACEL, PENTACEL ACTHIB COMPONENT, PENTACEL DTAP-IPV COMPONENT, PFIZER COVID 2024-25(5-11Y)EUA, PFIZER COVID 2024-25(6M-4Y)EUA, PNEUMOVAX 23, PREVNAR 20, QUADRACEL DTAP-IPV, RABAVERT, RECOMBIVAX HB, SHINGRIX, SHINGRIX GE ANTIGEN COMPONENT, SPIKEVAX 2024-2025, TDVAX, TENIVAC, TICOVAC, TRUMENBA, TWINRIX, TYPHIM VI, VAQTA, VAXELIS, VAXNEUVANCE
Capivasertib/Corticosteroids SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Capivasertib may cause severe hyperglycemia. Corticosteroids also cause hyperglycemia.(1) CLINICAL EFFECTS: Concurrent use of capivasertib with corticosteroids may cause severe hyperglycemia.(1) PREDISPOSING FACTORS: Patients with a medical history of diabetes mellitus and in patients with risk factors for hyperglycemia, such as obesity (BMI >= 30), elevated fasting glucose of > 160 mg/dL, HbA1c at or above the upper limit of normal, or intercurrent infections, may be at increased risk for hyperglycemia.(1) PATIENT MANAGEMENT: The US manufacturer of capivasertib recommends monitoring fasting blood glucose more frequently in patients on concomitant systemic corticosteroids.(1) If hyperglycemia occurs after starting capivasertib, monitor fasting glucose as clinically indicated and at least twice weekly until fasting glucose returns to normal.(1) DISCUSSION: Because capivasertib has been associated with severe hyperglycemia, fasting blood glucose should be monitored closely during the concurrent use of corticosteroids with capivasertib therapy.(1) In clinical studies, hyperglycemia occurred in 18% of patients treated with capivasertib. Grade 3 (insulin therapy initiated; hospitalization indicated) or Grade 4 (life-threatening consequences; urgent intervention indicated) hyperglycemia occurred in 2.8% of patients. Diabetic ketoacidosis occurred in 0.3% of patients and diabetic metabolic decompensation in 0.6% of patients. Dose reduction for hyperglycemia was required in 0.6% of patients and permanent discontinuation was required in 0.6% of patients. The median time to first occurrence of hyperglycemia was 15 days (range: 1 to 367).(1) In the 65 patients with hyperglycemia, 45% required treatment with anti-hyperglycemic medication (insulin in 15%, and metformin in 29%). Of the 29 patients who required anti-hyperglycemic medication during treatment with capivasertib, 66% (19/29) remained on these medications at treatment discontinuation or last follow up.(1)	TRUQAP

The following contraindication information is available for PRO-C-DURE 6 (triamcinolone acetonide):

Overview
Contraindicated
Severe
Moderate

Drug contraindication overview.

No enhanced Contraindications information available for this drug.

There are 7 contraindications. Absolute contraindication.

Contraindication List
Arginase deficiency
Argininosuccinate lyase deficiency
Carbamoyl phosphate synthetase deficiency
Cerebral malaria
Citrullinemia
Hyperammonemia associated with n-acetylglutamate synthase deficiency
Ornithine carbamoyltransferase deficiency

There are 23 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Amebae infection
Avascular necrosis of bone
Cataracts
Cerebral trauma
Chronic heart failure
Fungal infection
Gastritis
Inactive tuberculosis
Intestinal anastomosis
Measles
Measles contact
Myasthenia gravis
Ocular herpes simplex
Ocular hypertension
Osteopenia
Osteoporosis
Pheochromocytoma
Strongyloidiasis
Tendon rupture
Untreated active tuberculosis
Varicella contact
Varicella zoster virus infection
Viral hepatitis B

There are 19 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Diabetes mellitus
Diverticulitis of gastrointestinal tract
Edema
Hepatic cirrhosis
Hypercholesterolemia
Hypertension
Hypokalemia
Hypothalamic-pituitary insufficiency
Hypothyroidism
Immunosuppression
Infection
Muscle atrophy
Myopathy
Myopathy with CK elevation
Open angle glaucoma
Pathological fracture
Peptic ulcer
Psychotic disorder
Seizure disorder

The following adverse reaction information is available for PRO-C-DURE 6 (triamcinolone acetonide):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 45 severe adverse reactions.

More Frequent	Less Frequent
Infection	Adrenocortical insufficiency Diabetes mellitus Gastrointestinal hemorrhage Hypercortisolism Osteoporosis

Rare/Very Rare
Abnormal hepatic function tests Anaphylaxis Angioedema Bradycardia Bronchospastic pulmonary disease Cardiac arrhythmia Central serous chorioretinopathy Chronic heart failure Drug-induced psychosis Fat embolism Fracture Fungal infection Gastrointestinal perforation Glaucoma Hepatitis Hepatomegaly Hypertension Hypokalemia Hypothalamic-pituitary insufficiency Idiopathic intracranial hypertension Impaired wound healing Kaposi's sarcoma Leukocytosis Myopathy Ocular hypertension Osteopenia Pancreatitis Peptic ulcer Pheochromocytoma Pulmonary edema Pulmonary thromboembolism Seizure disorder Skin atrophy Tendon rupture Thromboembolic disorder Thrombophlebitis Tumor lysis syndrome Urticaria Vasculitis

Rare/Very Rare

Abnormal hepatic function tests
Anaphylaxis
Angioedema
Bradycardia
Bronchospastic pulmonary disease
Cardiac arrhythmia
Central serous chorioretinopathy
Chronic heart failure
Drug-induced psychosis
Fat embolism
Fracture
Fungal infection
Gastrointestinal perforation
Glaucoma
Hepatitis
Hepatomegaly
Hypertension
Hypokalemia
Hypothalamic-pituitary insufficiency
Idiopathic intracranial hypertension
Impaired wound healing
Kaposi's sarcoma
Leukocytosis
Myopathy
Ocular hypertension
Osteopenia
Pancreatitis
Peptic ulcer
Pheochromocytoma
Pulmonary edema
Pulmonary thromboembolism
Seizure disorder
Skin atrophy
Tendon rupture
Thromboembolic disorder
Thrombophlebitis
Tumor lysis syndrome
Urticaria
Vasculitis

There are 61 less severe adverse reactions.

More Frequent	Less Frequent
Gastric acid hypersecretory conditions Hyperglycemia Insomnia Steroid-induced hyperglycemia	Body fluid retention Bruising Cough Hypernatremia Injection site sequelae Irregular menstrual periods Malaise Sinusitis

Rare/Very Rare
Abdominal distension Acne vulgaris Acute cognitive impairment Allergic dermatitis Anticholinergic toxicity Arthralgia Arthritis Blurred vision Cataracts Depression Dry skin Ecchymosis Edema Erythema Esophagitis Euphoria Exophthalmos Facial edema Fatigue Flushing Genital organ pruritus Headache disorder Hiccups Hirsutism Hypercalcinuria Hyperhidrosis Increased appetite Injection site infection Lipodystrophy Memory impairment Mood changes Muscle spasm Muscle weakness Myalgia Nausea Ocular infection Oligospermia Paresthesia Peripheral sensory neuropathy Personality disorders Petechiae Postmenopausal bleeding Pruritus of skin Skin hypopigmentation Skin rash Syncope Tachycardia Vertigo Weight gain

Rare/Very Rare

Abdominal distension
Acne vulgaris
Acute cognitive impairment
Allergic dermatitis
Anticholinergic toxicity
Arthralgia
Arthritis
Blurred vision
Cataracts
Depression
Dry skin
Ecchymosis
Edema
Erythema
Esophagitis
Euphoria
Exophthalmos
Facial edema
Fatigue
Flushing
Genital organ pruritus
Headache disorder
Hiccups
Hirsutism
Hypercalcinuria
Hyperhidrosis
Increased appetite
Injection site infection
Lipodystrophy
Memory impairment
Mood changes
Muscle spasm
Muscle weakness
Myalgia
Nausea
Ocular infection
Oligospermia
Paresthesia
Peripheral sensory neuropathy
Personality disorders
Petechiae
Postmenopausal bleeding
Pruritus of skin
Skin hypopigmentation
Skin rash
Syncope
Tachycardia
Vertigo
Weight gain

The following precautions are available for PRO-C-DURE 6 (triamcinolone acetonide):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.

The following icd codes are available for PRO-C-DURE 6 (triamcinolone acetonide)'s list of indications:

Acquired thrombocytopenia
D69.5	Secondary thrombocytopenia
D69.59	Other secondary thrombocytopenia
Acute exacerbation of multiple sclerosis
G35	Multiple sclerosis
Acute gouty arthritis
M10	Gout
M10.0	Idiopathic gout
M10.00	Idiopathic gout, unspecified site
M10.01	Idiopathic gout, shoulder
M10.011	Idiopathic gout, right shoulder
M10.012	Idiopathic gout, left shoulder
M10.019	Idiopathic gout, unspecified shoulder
M10.02	Idiopathic gout, elbow
M10.021	Idiopathic gout, right elbow
M10.022	Idiopathic gout, left elbow
M10.029	Idiopathic gout, unspecified elbow
M10.03	Idiopathic gout, wrist
M10.031	Idiopathic gout, right wrist
M10.032	Idiopathic gout, left wrist
M10.039	Idiopathic gout, unspecified wrist
M10.04	Idiopathic gout, hand
M10.041	Idiopathic gout, right hand
M10.042	Idiopathic gout, left hand
M10.049	Idiopathic gout, unspecified hand
M10.05	Idiopathic gout, hip
M10.051	Idiopathic gout, right hip
M10.052	Idiopathic gout, left hip
M10.059	Idiopathic gout, unspecified hip
M10.06	Idiopathic gout, knee
M10.061	Idiopathic gout, right knee
M10.062	Idiopathic gout, left knee
M10.069	Idiopathic gout, unspecified knee
M10.07	Idiopathic gout, ankle and foot
M10.071	Idiopathic gout, right ankle and foot
M10.072	Idiopathic gout, left ankle and foot
M10.079	Idiopathic gout, unspecified ankle and foot
M10.08	Idiopathic gout, vertebrae
M10.09	Idiopathic gout, multiple sites
M10.1	Lead-induced gout
M10.10	Lead-induced gout, unspecified site
M10.11	Lead-induced gout, shoulder
M10.111	Lead-induced gout, right shoulder
M10.112	Lead-induced gout, left shoulder
M10.119	Lead-induced gout, unspecified shoulder
M10.12	Lead-induced gout, elbow
M10.121	Lead-induced gout, right elbow
M10.122	Lead-induced gout, left elbow
M10.129	Lead-induced gout, unspecified elbow
M10.13	Lead-induced gout, wrist
M10.131	Lead-induced gout, right wrist
M10.132	Lead-induced gout, left wrist
M10.139	Lead-induced gout, unspecified wrist
M10.14	Lead-induced gout, hand
M10.141	Lead-induced gout, right hand
M10.142	Lead-induced gout, left hand
M10.149	Lead-induced gout, unspecified hand
M10.15	Lead-induced gout, hip
M10.151	Lead-induced gout, right hip
M10.152	Lead-induced gout, left hip
M10.159	Lead-induced gout, unspecified hip
M10.16	Lead-induced gout, knee
M10.161	Lead-induced gout, right knee
M10.162	Lead-induced gout, left knee
M10.169	Lead-induced gout, unspecified knee
M10.17	Lead-induced gout, ankle and foot
M10.171	Lead-induced gout, right ankle and foot
M10.172	Lead-induced gout, left ankle and foot
M10.179	Lead-induced gout, unspecified ankle and foot
M10.18	Lead-induced gout, vertebrae
M10.19	Lead-induced gout, multiple sites
M10.2	Drug-induced gout
M10.20	Drug-induced gout, unspecified site
M10.21	Drug-induced gout, shoulder
M10.211	Drug-induced gout, right shoulder
M10.212	Drug-induced gout, left shoulder
M10.219	Drug-induced gout, unspecified shoulder
M10.22	Drug-induced gout, elbow
M10.221	Drug-induced gout, right elbow
M10.222	Drug-induced gout, left elbow
M10.229	Drug-induced gout, unspecified elbow
M10.23	Drug-induced gout, wrist
M10.231	Drug-induced gout, right wrist
M10.232	Drug-induced gout, left wrist
M10.239	Drug-induced gout, unspecified wrist
M10.24	Drug-induced gout, hand
M10.241	Drug-induced gout, right hand
M10.242	Drug-induced gout, left hand
M10.249	Drug-induced gout, unspecified hand
M10.25	Drug-induced gout, hip
M10.251	Drug-induced gout, right hip
M10.252	Drug-induced gout, left hip
M10.259	Drug-induced gout, unspecified hip
M10.26	Drug-induced gout, knee
M10.261	Drug-induced gout, right knee
M10.262	Drug-induced gout, left knee
M10.269	Drug-induced gout, unspecified knee
M10.27	Drug-induced gout, ankle and foot
M10.271	Drug-induced gout, right ankle and foot
M10.272	Drug-induced gout, left ankle and foot
M10.279	Drug-induced gout, unspecified ankle and foot
M10.28	Drug-induced gout, vertebrae
M10.29	Drug-induced gout, multiple sites
M10.3	Gout due to renal impairment
M10.30	Gout due to renal impairment, unspecified site
M10.31	Gout due to renal impairment, shoulder
M10.311	Gout due to renal impairment, right shoulder
M10.312	Gout due to renal impairment, left shoulder
M10.319	Gout due to renal impairment, unspecified shoulder
M10.32	Gout due to renal impairment, elbow
M10.321	Gout due to renal impairment, right elbow
M10.322	Gout due to renal impairment, left elbow
M10.329	Gout due to renal impairment, unspecified elbow
M10.33	Gout due to renal impairment, wrist
M10.331	Gout due to renal impairment, right wrist
M10.332	Gout due to renal impairment, left wrist
M10.339	Gout due to renal impairment, unspecified wrist
M10.34	Gout due to renal impairment, hand
M10.341	Gout due to renal impairment, right hand
M10.342	Gout due to renal impairment, left hand
M10.349	Gout due to renal impairment, unspecified hand
M10.35	Gout due to renal impairment, hip
M10.351	Gout due to renal impairment, right hip
M10.352	Gout due to renal impairment, left hip
M10.359	Gout due to renal impairment, unspecified hip
M10.36	Gout due to renal impairment, knee
M10.361	Gout due to renal impairment, right knee
M10.362	Gout due to renal impairment, left knee
M10.369	Gout due to renal impairment, unspecified knee
M10.37	Gout due to renal impairment, ankle and foot
M10.371	Gout due to renal impairment, right ankle and foot
M10.372	Gout due to renal impairment, left ankle and foot
M10.379	Gout due to renal impairment, unspecified ankle and foot
M10.38	Gout due to renal impairment, vertebrae
M10.39	Gout due to renal impairment, multiple sites
M10.4	Other secondary gout
M10.40	Other secondary gout, unspecified site
M10.41	Other secondary gout, shoulder
M10.411	Other secondary gout, right shoulder
M10.412	Other secondary gout, left shoulder
M10.419	Other secondary gout, unspecified shoulder
M10.42	Other secondary gout, elbow
M10.421	Other secondary gout, right elbow
M10.422	Other secondary gout, left elbow
M10.429	Other secondary gout, unspecified elbow
M10.43	Other secondary gout, wrist
M10.431	Other secondary gout, right wrist
M10.432	Other secondary gout, left wrist
M10.439	Other secondary gout, unspecified wrist
M10.44	Other secondary gout, hand
M10.441	Other secondary gout, right hand
M10.442	Other secondary gout, left hand
M10.449	Other secondary gout, unspecified hand
M10.45	Other secondary gout, hip
M10.451	Other secondary gout, right hip
M10.452	Other secondary gout, left hip
M10.459	Other secondary gout, unspecified hip
M10.46	Other secondary gout, knee
M10.461	Other secondary gout, right knee
M10.462	Other secondary gout, left knee
M10.469	Other secondary gout, unspecified knee
M10.47	Other secondary gout, ankle and foot
M10.471	Other secondary gout, right ankle and foot
M10.472	Other secondary gout, left ankle and foot
M10.479	Other secondary gout, unspecified ankle and foot
M10.48	Other secondary gout, vertebrae
M10.49	Other secondary gout, multiple sites
M10.9	Gout, unspecified
Acute lymphoid leukemia
C91.0	Acute lymphoblastic leukemia [ALl]
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.02	Acute lymphoblastic leukemia, in relapse
Acute rheumatic carditis
I01	Rheumatic fever with heart involvement
I01.0	Acute rheumatic pericarditis
I01.1	Acute rheumatic endocarditis
I01.2	Acute rheumatic myocarditis
I01.8	Other acute rheumatic heart disease
I01.9	Acute rheumatic heart disease, unspecified
Adrenocortical insufficiency
E27.1	Primary adrenocortical insufficiency
E27.2	Addisonian crisis
E27.3	Drug-induced adrenocortical insufficiency
E27.4	Other and unspecified adrenocortical insufficiency
E27.40	Unspecified adrenocortical insufficiency
E27.49	Other adrenocortical insufficiency
Adrenogenital disorder
E25	Adrenogenital disorders
E25.0	Congenital adrenogenital disorders associated with enzyme deficiency
E25.8	Other adrenogenital disorders
E25.9	Adrenogenital disorder, unspecified
Angioedema
T78.3xxA	Angioneurotic edema, initial encounter
Ankylosing spondylitis
M08.1	Juvenile ankylosing spondylitis
M45	Ankylosing spondylitis
M45.0	Ankylosing spondylitis of multiple sites in spine
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region
M45.2	Ankylosing spondylitis of cervical region
M45.3	Ankylosing spondylitis of cervicothoracic region
M45.4	Ankylosing spondylitis of thoracic region
M45.5	Ankylosing spondylitis of thoracolumbar region
M45.6	Ankylosing spondylitis lumbar region
M45.7	Ankylosing spondylitis of lumbosacral region
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region
M45.9	Ankylosing spondylitis of unspecified sites in spine
Aspiration pneumonitis
J69	Pneumonitis due to solids and liquids
J69.0	Pneumonitis due to inhalation of food and vomit
J69.1	Pneumonitis due to inhalation of oils and essences
J69.8	Pneumonitis due to inhalation of other solids and liquids
O29.01	Aspiration pneumonitis due to anesthesia during pregnancy
O29.011	Aspiration pneumonitis due to anesthesia during pregnancy, first trimester
O29.012	Aspiration pneumonitis due to anesthesia during pregnancy, second trimester
O29.013	Aspiration pneumonitis due to anesthesia during pregnancy, third trimester
O29.019	Aspiration pneumonitis due to anesthesia during pregnancy, unspecified trimester
O74.0	Aspiration pneumonitis due to anesthesia during labor and delivery
O89.01	Aspiration pneumonitis due to anesthesia during the puerperium
P24.01	Meconium aspiration with respiratory symptoms
P24.11	Neonatal aspiration of (clear) amniotic fluid and mucus with respiratory symptoms
P24.21	Neonatal aspiration of blood with respiratory symptoms
P24.31	Neonatal aspiration of milk and regurgitated food with respiratory symptoms
P24.81	Other neonatal aspiration with respiratory symptoms
Atopic dermatitis
L20	Atopic dermatitis
L20.0	Besnier's prurigo
L20.8	Other atopic dermatitis
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L20.9	Atopic dermatitis, unspecified
Autoimmune hemolytic anemia
D59.0	Drug-induced autoimmune hemolytic anemia
D59.1	Other autoimmune hemolytic anemias
D59.10	Autoimmune hemolytic anemia, unspecified
D59.11	Warm autoimmune hemolytic anemia
D59.12	Cold autoimmune hemolytic anemia
D59.13	Mixed type autoimmune hemolytic anemia
D59.19	Other autoimmune hemolytic anemia
Berylliosis
J63.2	Berylliosis
Bursitis
M70.1	Bursitis of hand
M70.10	Bursitis, unspecified hand
M70.11	Bursitis, right hand
M70.12	Bursitis, left hand
M70.2	Olecranon bursitis
M70.20	Olecranon bursitis, unspecified elbow
M70.21	Olecranon bursitis, right elbow
M70.22	Olecranon bursitis, left elbow
M70.3	Other bursitis of elbow
M70.30	Other bursitis of elbow, unspecified elbow
M70.31	Other bursitis of elbow, right elbow
M70.32	Other bursitis of elbow, left elbow
M70.4	Prepatellar bursitis
M70.40	Prepatellar bursitis, unspecified knee
M70.41	Prepatellar bursitis, right knee
M70.42	Prepatellar bursitis, left knee
M70.5	Other bursitis of knee
M70.50	Other bursitis of knee, unspecified knee
M70.51	Other bursitis of knee, right knee
M70.52	Other bursitis of knee, left knee
M70.6	Trochanteric bursitis
M70.60	Trochanteric bursitis, unspecified hip
M70.61	Trochanteric bursitis, right hip
M70.62	Trochanteric bursitis, left hip
M70.7	Other bursitis of hip
M70.70	Other bursitis of hip, unspecified hip
M70.71	Other bursitis of hip, right hip
M70.72	Other bursitis of hip, left hip
M71.5	Other bursitis, not elsewhere classified
M71.50	Other bursitis, not elsewhere classified, unspecified site
M71.52	Other bursitis, not elsewhere classified, elbow
M71.521	Other bursitis, not elsewhere classified, right elbow
M71.522	Other bursitis, not elsewhere classified, left elbow
M71.529	Other bursitis, not elsewhere classified, unspecified elbow
M71.53	Other bursitis, not elsewhere classified, wrist
M71.531	Other bursitis, not elsewhere classified, right wrist
M71.532	Other bursitis, not elsewhere classified, left wrist
M71.539	Other bursitis, not elsewhere classified, unspecified wrist
M71.54	Other bursitis, not elsewhere classified, hand
M71.541	Other bursitis, not elsewhere classified, right hand
M71.542	Other bursitis, not elsewhere classified, left hand
M71.549	Other bursitis, not elsewhere classified, unspecified hand
M71.55	Other bursitis, not elsewhere classified, hip
M71.551	Other bursitis, not elsewhere classified, right hip
M71.552	Other bursitis, not elsewhere classified, left hip
M71.559	Other bursitis, not elsewhere classified, unspecified hip
M71.56	Other bursitis, not elsewhere classified, knee
M71.561	Other bursitis, not elsewhere classified, right knee
M71.562	Other bursitis, not elsewhere classified, left knee
M71.569	Other bursitis, not elsewhere classified, unspecified knee
M71.57	Other bursitis, not elsewhere classified, ankle and foot
M71.571	Other bursitis, not elsewhere classified, right ankle and foot
M71.572	Other bursitis, not elsewhere classified, left ankle and foot
M71.579	Other bursitis, not elsewhere classified, unspecified ankle and foot
M71.58	Other bursitis, not elsewhere classified, other site
M75.5	Bursitis of shoulder
M75.50	Bursitis of unspecified shoulder
M75.51	Bursitis of right shoulder
M75.52	Bursitis of left shoulder
M76.4	Tibial collateral bursitis [pellegrini-stieda]
M76.40	Tibial collateral bursitis [pellegrini-stieda], unspecified leg
M76.41	Tibial collateral bursitis [pellegrini-stieda], right leg
M76.42	Tibial collateral bursitis [pellegrini-stieda], left leg
Cerebral edema
G93.6	Cerebral edema
P11.0	Cerebral edema due to birth injury
Contact dermatitis
L23	Allergic contact dermatitis
L23.0	Allergic contact dermatitis due to metals
L23.1	Allergic contact dermatitis due to adhesives
L23.2	Allergic contact dermatitis due to cosmetics
L23.3	Allergic contact dermatitis due to drugs in contact with skin
L23.4	Allergic contact dermatitis due to dyes
L23.5	Allergic contact dermatitis due to other chemical products
L23.6	Allergic contact dermatitis due to food in contact with the skin
L23.7	Allergic contact dermatitis due to plants, except food
L23.8	Allergic contact dermatitis due to other agents
L23.81	Allergic contact dermatitis due to animal (cat) (dog) dander
L23.89	Allergic contact dermatitis due to other agents
L23.9	Allergic contact dermatitis, unspecified cause
L24	Irritant contact dermatitis
L24.0	Irritant contact dermatitis due to detergents
L24.1	Irritant contact dermatitis due to oils and greases
L24.2	Irritant contact dermatitis due to solvents
L24.3	Irritant contact dermatitis due to cosmetics
L24.4	Irritant contact dermatitis due to drugs in contact with skin
L24.5	Irritant contact dermatitis due to other chemical products
L24.6	Irritant contact dermatitis due to food in contact with skin
L24.7	Irritant contact dermatitis due to plants, except food
L24.8	Irritant contact dermatitis due to other agents
L24.81	Irritant contact dermatitis due to metals
L24.89	Irritant contact dermatitis due to other agents
L24.9	Irritant contact dermatitis, unspecified cause
L24.A0	Irritant contact dermatitis due to friction or contact with body fluids, unspecified
L24.A1	Irritant contact dermatitis due to saliva
L24.A2	Irritant contact dermatitis due to fecal, urinary or dual incontinence
L24.A9	Irritant contact dermatitis due friction or contact with other specified body fluids
L24.B	Irritant contact dermatitis related to stoma or fistula
L24.B0	Irritant contact dermatitis related to unspecified stoma or fistula
L24.B1	Irritant contact dermatitis related to digestive stoma or fistula
L24.B2	Irritant contact dermatitis related to respiratory stoma or fistula
L24.B3	Irritant contact dermatitis related to fecal or urinary stoma or fistula
L25	Unspecified contact dermatitis
L25.0	Unspecified contact dermatitis due to cosmetics
L25.1	Unspecified contact dermatitis due to drugs in contact with skin
L25.2	Unspecified contact dermatitis due to dyes
L25.3	Unspecified contact dermatitis due to other chemical products
L25.4	Unspecified contact dermatitis due to food in contact with skin
L25.5	Unspecified contact dermatitis due to plants, except food
L25.8	Unspecified contact dermatitis due to other agents
L25.9	Unspecified contact dermatitis, unspecified cause
Crohn's disease
K50	Crohn's disease [regional enteritis]
K50.0	Crohn's disease of small intestine
K50.00	Crohn's disease of small intestine without complications
K50.01	Crohn's disease of small intestine with complications
K50.011	Crohn's disease of small intestine with rectal bleeding
K50.012	Crohn's disease of small intestine with intestinal obstruction
K50.013	Crohn's disease of small intestine with fistula
K50.014	Crohn's disease of small intestine with abscess
K50.018	Crohn's disease of small intestine with other complication
K50.019	Crohn's disease of small intestine with unspecified complications
K50.1	Crohn's disease of large intestine
K50.10	Crohn's disease of large intestine without complications
K50.11	Crohn's disease of large intestine with complications
K50.111	Crohn's disease of large intestine with rectal bleeding
K50.112	Crohn's disease of large intestine with intestinal obstruction
K50.113	Crohn's disease of large intestine with fistula
K50.114	Crohn's disease of large intestine with abscess
K50.118	Crohn's disease of large intestine with other complication
K50.119	Crohn's disease of large intestine with unspecified complications
K50.8	Crohn's disease of both small and large intestine
K50.80	Crohn's disease of both small and large intestine without complications
K50.81	Crohn's disease of both small and large intestine with complications
K50.811	Crohn's disease of both small and large intestine with rectal bleeding
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction
K50.813	Crohn's disease of both small and large intestine with fistula
K50.814	Crohn's disease of both small and large intestine with abscess
K50.818	Crohn's disease of both small and large intestine with other complication
K50.819	Crohn's disease of both small and large intestine with unspecified complications
K50.9	Crohn's disease, unspecified
K50.90	Crohn's disease, unspecified, without complications
K50.91	Crohn's disease, unspecified, with complications
K50.911	Crohn's disease, unspecified, with rectal bleeding
K50.912	Crohn's disease, unspecified, with intestinal obstruction
K50.913	Crohn's disease, unspecified, with fistula
K50.914	Crohn's disease, unspecified, with abscess
K50.918	Crohn's disease, unspecified, with other complication
K50.919	Crohn's disease, unspecified, with unspecified complications
Dermatitis herpetiformis
L12.2	Chronic bullous disease of childhood
L13.0	Dermatitis herpetiformis
Diamond blackfan anemia
D61.01	Constitutional (pure) red blood cell aplasia
Erythema multiforme
L51	Erythema multiforme
L51.0	Nonbullous erythema multiforme
L51.1	Stevens-johnson syndrome
L51.2	Toxic epidermal necrolysis [lyell]
L51.3	Stevens-johnson syndrome-toxic epidermal necrolysis overlap syndrome
L51.8	Other erythema multiforme
L51.9	Erythema multiforme, unspecified
Erythroblastic anemia
D60	Acquired pure red cell aplasia [erythroblastopenia]
D60.0	Chronic acquired pure red cell aplasia
D60.1	Transient acquired pure red cell aplasia
D60.8	Other acquired pure red cell aplasias
D60.9	Acquired pure red cell aplasia, unspecified
D61.01	Constitutional (pure) red blood cell aplasia
Exfoliative dermatitis
L26	Exfoliative dermatitis
Hodgkin's lymphoma
C81	Hodgkin lymphoma
C81.0	Nodular lymphocyte predominant hodgkin lymphoma
C81.00	Nodular lymphocyte predominant hodgkin lymphoma, unspecified site
C81.01	Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of head, face, and neck
C81.02	Nodular lymphocyte predominant hodgkin lymphoma, intrathoracic lymph nodes
C81.03	Nodular lymphocyte predominant hodgkin lymphoma, intra-abdominal lymph nodes
C81.04	Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.05	Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.06	Nodular lymphocyte predominant hodgkin lymphoma, intrapelvic lymph nodes
C81.07	Nodular lymphocyte predominant hodgkin lymphoma, spleen
C81.08	Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of multiple sites
C81.09	Nodular lymphocyte predominant hodgkin lymphoma, extranodal and solid organ sites
C81.1	Nodular sclerosis hodgkin lymphoma
C81.10	Nodular sclerosis hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis hodgkin lymphoma, intra-abdominal lymph nodes
C81.14	Nodular sclerosis hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis hodgkin lymphoma, spleen
C81.18	Nodular sclerosis hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis hodgkin lymphoma, extranodal and solid organ sites
C81.2	Mixed cellularity hodgkin lymphoma
C81.20	Mixed cellularity hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.26	Mixed cellularity hodgkin lymphoma, intrapelvic lymph nodes
C81.27	Mixed cellularity hodgkin lymphoma, spleen
C81.28	Mixed cellularity hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity hodgkin lymphoma, extranodal and solid organ sites
C81.3	Lymphocyte depleted hodgkin lymphoma
C81.30	Lymphocyte depleted hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted hodgkin lymphoma, extranodal and solid organ sites
C81.4	Lymphocyte-rich hodgkin lymphoma
C81.40	Lymphocyte-rich hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich hodgkin lymphoma, extranodal and solid organ sites
C81.7	Other hodgkin lymphoma
C81.70	Other hodgkin lymphoma, unspecified site
C81.71	Other hodgkin lymphoma, lymph nodes of head, face, and neck
C81.72	Other hodgkin lymphoma, intrathoracic lymph nodes
C81.73	Other hodgkin lymphoma, intra-abdominal lymph nodes
C81.74	Other hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.75	Other hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.76	Other hodgkin lymphoma, intrapelvic lymph nodes
C81.77	Other hodgkin lymphoma, spleen
C81.78	Other hodgkin lymphoma, lymph nodes of multiple sites
C81.79	Other hodgkin lymphoma, extranodal and solid organ sites
C81.9	Hodgkin lymphoma, unspecified
C81.90	Hodgkin lymphoma, unspecified, unspecified site
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified, spleen
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites
Humoral hypercalcemia of malignancy
E83.52	Hypercalcemia
Hypersensitivity drug reaction
T88.7xxA	Unspecified adverse effect of drug or medicament, initial encounter
Idiopathic thrombocytopenic purpura
D69.3	Immune thrombocytopenic purpura
Inflammatory bowel disease
K50	Crohn's disease [regional enteritis]
K50.0	Crohn's disease of small intestine
K50.01	Crohn's disease of small intestine with complications
K50.011	Crohn's disease of small intestine with rectal bleeding
K50.012	Crohn's disease of small intestine with intestinal obstruction
K50.013	Crohn's disease of small intestine with fistula
K50.014	Crohn's disease of small intestine with abscess
K50.018	Crohn's disease of small intestine with other complication
K50.019	Crohn's disease of small intestine with unspecified complications
K50.1	Crohn's disease of large intestine
K50.11	Crohn's disease of large intestine with complications
K50.111	Crohn's disease of large intestine with rectal bleeding
K50.112	Crohn's disease of large intestine with intestinal obstruction
K50.113	Crohn's disease of large intestine with fistula
K50.114	Crohn's disease of large intestine with abscess
K50.118	Crohn's disease of large intestine with other complication
K50.119	Crohn's disease of large intestine with unspecified complications
K50.8	Crohn's disease of both small and large intestine
K50.81	Crohn's disease of both small and large intestine with complications
K50.811	Crohn's disease of both small and large intestine with rectal bleeding
K50.812	Crohn's disease of both small and large intestine with intestinal obstruction
K50.813	Crohn's disease of both small and large intestine with fistula
K50.814	Crohn's disease of both small and large intestine with abscess
K50.818	Crohn's disease of both small and large intestine with other complication
K50.819	Crohn's disease of both small and large intestine with unspecified complications
K50.9	Crohn's disease, unspecified
K50.91	Crohn's disease, unspecified, with complications
K50.911	Crohn's disease, unspecified, with rectal bleeding
K50.912	Crohn's disease, unspecified, with intestinal obstruction
K50.913	Crohn's disease, unspecified, with fistula
K50.914	Crohn's disease, unspecified, with abscess
K50.918	Crohn's disease, unspecified, with other complication
K50.919	Crohn's disease, unspecified, with unspecified complications
K51	Ulcerative colitis
K51.0	Ulcerative (chronic) pancolitis
K51.01	Ulcerative (chronic) pancolitis with complications
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction
K51.013	Ulcerative (chronic) pancolitis with fistula
K51.014	Ulcerative (chronic) pancolitis with abscess
K51.018	Ulcerative (chronic) pancolitis with other complication
K51.019	Ulcerative (chronic) pancolitis with unspecified complications
K51.2	Ulcerative (chronic) proctitis
K51.21	Ulcerative (chronic) proctitis with complications
K51.211	Ulcerative (chronic) proctitis with rectal bleeding
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction
K51.213	Ulcerative (chronic) proctitis with fistula
K51.214	Ulcerative (chronic) proctitis with abscess
K51.218	Ulcerative (chronic) proctitis with other complication
K51.219	Ulcerative (chronic) proctitis with unspecified complications
K51.3	Ulcerative (chronic) rectosigmoiditis
K51.31	Ulcerative (chronic) rectosigmoiditis with complications
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications
K51.4	Inflammatory polyps of colon
K51.41	Inflammatory polyps of colon with complications
K51.411	Inflammatory polyps of colon with rectal bleeding
K51.412	Inflammatory polyps of colon with intestinal obstruction
K51.413	Inflammatory polyps of colon with fistula
K51.414	Inflammatory polyps of colon with abscess
K51.418	Inflammatory polyps of colon with other complication
K51.419	Inflammatory polyps of colon with unspecified complications
K51.5	Left sided colitis
K51.51	Left sided colitis with complications
K51.511	Left sided colitis with rectal bleeding
K51.512	Left sided colitis with intestinal obstruction
K51.513	Left sided colitis with fistula
K51.514	Left sided colitis with abscess
K51.518	Left sided colitis with other complication
K51.519	Left sided colitis with unspecified complications
K51.8	Other ulcerative colitis
K51.81	Other ulcerative colitis with complications
K51.811	Other ulcerative colitis with rectal bleeding
K51.812	Other ulcerative colitis with intestinal obstruction
K51.813	Other ulcerative colitis with fistula
K51.814	Other ulcerative colitis with abscess
K51.818	Other ulcerative colitis with other complication
K51.819	Other ulcerative colitis with unspecified complications
K51.9	Ulcerative colitis, unspecified
K51.91	Ulcerative colitis, unspecified, with complications
K51.911	Ulcerative colitis, unspecified with rectal bleeding
K51.912	Ulcerative colitis, unspecified with intestinal obstruction
K51.913	Ulcerative colitis, unspecified with fistula
K51.914	Ulcerative colitis, unspecified with abscess
K51.918	Ulcerative colitis, unspecified with other complication
K51.919	Ulcerative colitis, unspecified with unspecified complications
K52.3	Indeterminate colitis
Juvenile idiopathic arthritis
M08.0	Unspecified juvenile rheumatoid arthritis
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site
M08.01	Unspecified juvenile rheumatoid arthritis, shoulder
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder
M08.02	Unspecified juvenile rheumatoid arthritis of elbow
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow
M08.03	Unspecified juvenile rheumatoid arthritis, wrist
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist
M08.04	Unspecified juvenile rheumatoid arthritis, hand
M08.041	Unspecified juvenile rheumatoid arthritis, right hand
M08.042	Unspecified juvenile rheumatoid arthritis, left hand
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand
M08.05	Unspecified juvenile rheumatoid arthritis, hip
M08.051	Unspecified juvenile rheumatoid arthritis, right hip
M08.052	Unspecified juvenile rheumatoid arthritis, left hip
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip
M08.06	Unspecified juvenile rheumatoid arthritis, knee
M08.061	Unspecified juvenile rheumatoid arthritis, right knee
M08.062	Unspecified juvenile rheumatoid arthritis, left knee
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee
M08.07	Unspecified juvenile rheumatoid arthritis, ankle and foot
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site
M08.2	Juvenile rheumatoid arthritis with systemic onset
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site
M08.21	Juvenile rheumatoid arthritis with systemic onset, shoulder
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder
M08.22	Juvenile rheumatoid arthritis with systemic onset, elbow
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow
M08.23	Juvenile rheumatoid arthritis with systemic onset, wrist
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist
M08.24	Juvenile rheumatoid arthritis with systemic onset, hand
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand
M08.25	Juvenile rheumatoid arthritis with systemic onset, hip
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip
M08.26	Juvenile rheumatoid arthritis with systemic onset, knee
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee
M08.27	Juvenile rheumatoid arthritis with systemic onset, ankle and foot
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site
M08.3	Juvenile rheumatoid polyarthritis (seronegative)
M08.4	Pauciarticular juvenile rheumatoid arthritis
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site
M08.41	Pauciarticular juvenile rheumatoid arthritis, shoulder
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder
M08.42	Pauciarticular juvenile rheumatoid arthritis, elbow
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow
M08.43	Pauciarticular juvenile rheumatoid arthritis, wrist
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist
M08.44	Pauciarticular juvenile rheumatoid arthritis, hand
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand
M08.45	Pauciarticular juvenile rheumatoid arthritis, hip
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip
M08.46	Pauciarticular juvenile rheumatoid arthritis, knee
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee
M08.47	Pauciarticular juvenile rheumatoid arthritis, ankle and foot
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site
Laryngeal edema
J38.4	Edema of larynx
Loffler syndrome
J82.82	Acute eosinophilic pneumonia
Mycosis fungoides
C84.0	Mycosis fungoides
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
Nephrotic syndrome
N04	Nephrotic syndrome
N04.0	Nephrotic syndrome with minor glomerular abnormality
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified
N04.21	Primary membranous nephropathy with nephrotic syndrome
N04.22	Secondary membranous nephropathy with nephrotic syndrome
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis
N04.6	Nephrotic syndrome with dense deposit disease
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis
N04.8	Nephrotic syndrome with other morphologic changes
N04.9	Nephrotic syndrome with unspecified morphologic changes
N04.A	Nephrotic syndrome with c3 glomerulonephritis
Non-hodgkin's lymphoma
C82	Follicular lymphoma
C82.0	Follicular lymphoma grade I
C82.00	Follicular lymphoma grade i, unspecified site
C82.01	Follicular lymphoma grade i, lymph nodes of head, face, and neck
C82.02	Follicular lymphoma grade i, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade i, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade i, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade i, lymph nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade i, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade i, spleen
C82.08	Follicular lymphoma grade i, lymph nodes of multiple sites
C82.09	Follicular lymphoma grade i, extranodal and solid organ sites
C82.1	Follicular lymphoma grade II
C82.10	Follicular lymphoma grade Ii, unspecified site
C82.11	Follicular lymphoma grade Ii, lymph nodes of head, face, and neck
C82.12	Follicular lymphoma grade Ii, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade Ii, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade Ii, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade Ii, lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade Ii, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade Ii, spleen
C82.18	Follicular lymphoma grade Ii, lymph nodes of multiple sites
C82.19	Follicular lymphoma grade Ii, extranodal and solid organ sites
C82.2	Follicular lymphoma grade IIi, unspecified
C82.20	Follicular lymphoma grade IIi, unspecified, unspecified site
C82.21	Follicular lymphoma grade IIi, unspecified, lymph nodes of head, face, and neck
C82.22	Follicular lymphoma grade IIi, unspecified, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade IIi, unspecified, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade IIi, unspecified, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade IIi, unspecified, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade IIi, unspecified, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade IIi, unspecified, spleen
C82.28	Follicular lymphoma grade IIi, unspecified, lymph nodes of multiple sites
C82.29	Follicular lymphoma grade IIi, unspecified, extranodal and solid organ sites
C82.3	Follicular lymphoma grade IIia
C82.30	Follicular lymphoma grade IIia, unspecified site
C82.31	Follicular lymphoma grade IIia, lymph nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIia, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIia, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIia, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIia, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIia, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIia, spleen
C82.38	Follicular lymphoma grade IIia, lymph nodes of multiple sites
C82.39	Follicular lymphoma grade IIia, extranodal and solid organ sites
C82.4	Follicular lymphoma grade IIib
C82.40	Follicular lymphoma grade IIib, unspecified site
C82.41	Follicular lymphoma grade IIib, lymph nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIib, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIib, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIib, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIib, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIib, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIib, spleen
C82.48	Follicular lymphoma grade IIib, lymph nodes of multiple sites
C82.49	Follicular lymphoma grade IIib, extranodal and solid organ sites
C82.5	Diffuse follicle center lymphoma
C82.50	Diffuse follicle center lymphoma, unspecified site
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes
C82.57	Diffuse follicle center lymphoma, spleen
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites
C82.6	Cutaneous follicle center lymphoma
C82.60	Cutaneous follicle center lymphoma, unspecified site
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes
C82.67	Cutaneous follicle center lymphoma, spleen
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites
C82.8	Other types of follicular lymphoma
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites
C82.9	Follicular lymphoma, unspecified
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites
C83	Non-follicular lymphoma
C83.0	Small cell b-cell lymphoma
C83.00	Small cell b-cell lymphoma, unspecified site
C83.01	Small cell b-cell lymphoma, lymph nodes of head, face, and neck
C83.02	Small cell b-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell b-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell b-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell b-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell b-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell b-cell lymphoma, spleen
C83.08	Small cell b-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell b-cell lymphoma, extranodal and solid organ sites
C83.1	Mantle cell lymphoma
C83.10	Mantle cell lymphoma, unspecified site
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes
C83.17	Mantle cell lymphoma, spleen
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites
C83.19	Mantle cell lymphoma, extranodal and solid organ sites
C83.3	Diffuse large b-cell lymphoma
C83.30	Diffuse large b-cell lymphoma, unspecified site
C83.31	Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck
C83.32	Diffuse large b-cell lymphoma, intrathoracic lymph nodes
C83.33	Diffuse large b-cell lymphoma, intra-abdominal lymph nodes
C83.34	Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb
C83.35	Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.36	Diffuse large b-cell lymphoma, intrapelvic lymph nodes
C83.37	Diffuse large b-cell lymphoma, spleen
C83.38	Diffuse large b-cell lymphoma, lymph nodes of multiple sites
C83.39	Diffuse large b-cell lymphoma, extranodal and solid organ sites
C83.5	Lymphoblastic (diffuse) lymphoma
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
C83.7	Burkitt lymphoma
C83.70	Burkitt lymphoma, unspecified site
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck
C83.72	Burkitt lymphoma, intrathoracic lymph nodes
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb
C83.76	Burkitt lymphoma, intrapelvic lymph nodes
C83.77	Burkitt lymphoma, spleen
C83.78	Burkitt lymphoma, lymph nodes of multiple sites
C83.79	Burkitt lymphoma, extranodal and solid organ sites
C83.8	Other non-follicular lymphoma
C83.80	Other non-follicular lymphoma, unspecified site
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes
C83.87	Other non-follicular lymphoma, spleen
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites
C83.9	Non-follicular (diffuse) lymphoma, unspecified
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites
C84	Mature t/Nk-cell lymphomas
C84.0	Mycosis fungoides
C84.00	Mycosis fungoides, unspecified site
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck
C84.02	Mycosis fungoides, intrathoracic lymph nodes
C84.03	Mycosis fungoides, intra-abdominal lymph nodes
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb
C84.06	Mycosis fungoides, intrapelvic lymph nodes
C84.07	Mycosis fungoides, spleen
C84.08	Mycosis fungoides, lymph nodes of multiple sites
C84.09	Mycosis fungoides, extranodal and solid organ sites
C84.1	Sezary disease
C84.10	Sezary disease, unspecified site
C84.11	Sezary disease, lymph nodes of head, face, and neck
C84.12	Sezary disease, intrathoracic lymph nodes
C84.13	Sezary disease, intra-abdominal lymph nodes
C84.14	Sezary disease, lymph nodes of axilla and upper limb
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb
C84.16	Sezary disease, intrapelvic lymph nodes
C84.17	Sezary disease, spleen
C84.18	Sezary disease, lymph nodes of multiple sites
C84.19	Sezary disease, extranodal and solid organ sites
C84.4	Peripheral t-cell lymphoma, not elsewhere classified
C84.40	Peripheral t-cell lymphoma, not elsewhere classified, unspecified site
C84.41	Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of head, face, and neck
C84.42	Peripheral t-cell lymphoma, not elsewhere classified, intrathoracic lymph nodes
C84.43	Peripheral t-cell lymphoma, not elsewhere classified, intra-abdominal lymph nodes
C84.44	Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of axilla and upper limb
C84.45	Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of inguinal region and lower limb
C84.46	Peripheral t-cell lymphoma, not elsewhere classified, intrapelvic lymph nodes
C84.47	Peripheral t-cell lymphoma, not elsewhere classified, spleen
C84.48	Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of multiple sites
C84.49	Peripheral t-cell lymphoma, not elsewhere classified, extranodal and solid organ sites
C84.6	Anaplastic large cell lymphoma, ALk-positive
C84.60	Anaplastic large cell lymphoma, ALk-positive, unspecified site
C84.61	Anaplastic large cell lymphoma, ALk-positive, lymph nodes of head, face, and neck
C84.62	Anaplastic large cell lymphoma, ALk-positive, intrathoracic lymph nodes
C84.63	Anaplastic large cell lymphoma, ALk-positive, intra-abdominal lymph nodes
C84.64	Anaplastic large cell lymphoma, ALk-positive, lymph nodes of axilla and upper limb
C84.65	Anaplastic large cell lymphoma, ALk-positive, lymph nodes of inguinal region and lower limb
C84.66	Anaplastic large cell lymphoma, ALk-positive, intrapelvic lymph nodes
C84.67	Anaplastic large cell lymphoma, ALk-positive, spleen
C84.68	Anaplastic large cell lymphoma, ALk-positive, lymph nodes of multiple sites
C84.69	Anaplastic large cell lymphoma, ALk-positive, extranodal and solid organ sites
C84.7	Anaplastic large cell lymphoma, ALk-negative
C84.70	Anaplastic large cell lymphoma, ALk-negative, unspecified site
C84.71	Anaplastic large cell lymphoma, ALk-negative, lymph nodes of head, face, and neck
C84.72	Anaplastic large cell lymphoma, ALk-negative, intrathoracic lymph nodes
C84.73	Anaplastic large cell lymphoma, ALk-negative, intra-abdominal lymph nodes
C84.74	Anaplastic large cell lymphoma, ALk-negative, lymph nodes of axilla and upper limb
C84.75	Anaplastic large cell lymphoma, ALk-negative, lymph nodes of inguinal region and lower limb
C84.76	Anaplastic large cell lymphoma, ALk-negative, intrapelvic lymph nodes
C84.77	Anaplastic large cell lymphoma, ALk-negative, spleen
C84.78	Anaplastic large cell lymphoma, ALk-negative, lymph nodes of multiple sites
C84.79	Anaplastic large cell lymphoma, ALk-negative, extranodal and solid organ sites
C84.7A	Anaplastic large cell lymphoma, ALk-negative, breast
C84.9	Mature t/Nk-cell lymphomas, unspecified
C84.90	Mature t/Nk-cell lymphomas, unspecified, unspecified site
C84.91	Mature t/Nk-cell lymphomas, unspecified, lymph nodes of head, face, and neck
C84.92	Mature t/Nk-cell lymphomas, unspecified, intrathoracic lymph nodes
C84.93	Mature t/Nk-cell lymphomas, unspecified, intra-abdominal lymph nodes
C84.94	Mature t/Nk-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
C84.95	Mature t/Nk-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb
C84.96	Mature t/Nk-cell lymphomas, unspecified, intrapelvic lymph nodes
C84.97	Mature t/Nk-cell lymphomas, unspecified, spleen
C84.98	Mature t/Nk-cell lymphomas, unspecified, lymph nodes of multiple sites
C84.99	Mature t/Nk-cell lymphomas, unspecified, extranodal and solid organ sites
C84.A	Cutaneous t-cell lymphoma, unspecified
C84.A0	Cutaneous t-cell lymphoma, unspecified, unspecified site
C84.A1	Cutaneous t-cell lymphoma, unspecified lymph nodes of head, face, and neck
C84.A2	Cutaneous t-cell lymphoma, unspecified, intrathoracic lymph nodes
C84.A3	Cutaneous t-cell lymphoma, unspecified, intra-abdominal lymph nodes
C84.A4	Cutaneous t-cell lymphoma, unspecified, lymph nodes of axilla and upper limb
C84.A5	Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C84.A6	Cutaneous t-cell lymphoma, unspecified, intrapelvic lymph nodes
C84.A7	Cutaneous t-cell lymphoma, unspecified, spleen
C84.A8	Cutaneous t-cell lymphoma, unspecified, lymph nodes of multiple sites
C84.A9	Cutaneous t-cell lymphoma, unspecified, extranodal and solid organ sites
C84.Z	Other mature t/Nk-cell lymphomas
C84.Z0	Other mature t/Nk-cell lymphomas, unspecified site
C84.Z1	Other mature t/Nk-cell lymphomas, lymph nodes of head, face, and neck
C84.Z2	Other mature t/Nk-cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature t/Nk-cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature t/Nk-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5	Other mature t/Nk-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6	Other mature t/Nk-cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature t/Nk-cell lymphomas, spleen
C84.Z8	Other mature t/Nk-cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature t/Nk-cell lymphomas, extranodal and solid organ sites
C85	Other specified and unspecified types of non-hodgkin lymphoma
C85.1	Unspecified b-cell lymphoma
C85.10	Unspecified b-cell lymphoma, unspecified site
C85.11	Unspecified b-cell lymphoma, lymph nodes of head, face, and neck
C85.12	Unspecified b-cell lymphoma, intrathoracic lymph nodes
C85.13	Unspecified b-cell lymphoma, intra-abdominal lymph nodes
C85.14	Unspecified b-cell lymphoma, lymph nodes of axilla and upper limb
C85.15	Unspecified b-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.16	Unspecified b-cell lymphoma, intrapelvic lymph nodes
C85.17	Unspecified b-cell lymphoma, spleen
C85.18	Unspecified b-cell lymphoma, lymph nodes of multiple sites
C85.19	Unspecified b-cell lymphoma, extranodal and solid organ sites
C85.2	Mediastinal (thymic) large b-cell lymphoma
C85.20	Mediastinal (thymic) large b-cell lymphoma, unspecified site
C85.21	Mediastinal (thymic) large b-cell lymphoma, lymph nodes of head, face, and neck
C85.22	Mediastinal (thymic) large b-cell lymphoma, intrathoracic lymph nodes
C85.23	Mediastinal (thymic) large b-cell lymphoma, intra-abdominal lymph nodes
C85.24	Mediastinal (thymic) large b-cell lymphoma, lymph nodes of axilla and upper limb
C85.25	Mediastinal (thymic) large b-cell lymphoma, lymph nodes of inguinal region and lower limb
C85.26	Mediastinal (thymic) large b-cell lymphoma, intrapelvic lymph nodes
C85.27	Mediastinal (thymic) large b-cell lymphoma, spleen
C85.28	Mediastinal (thymic) large b-cell lymphoma, lymph nodes of multiple sites
C85.29	Mediastinal (thymic) large b-cell lymphoma, extranodal and solid organ sites
C85.8	Other specified types of non-hodgkin lymphoma
C85.80	Other specified types of non-hodgkin lymphoma, unspecified site
C85.81	Other specified types of non-hodgkin lymphoma, lymph nodes of head, face, and neck
C85.82	Other specified types of non-hodgkin lymphoma, intrathoracic lymph nodes
C85.83	Other specified types of non-hodgkin lymphoma, intra-abdominal lymph nodes
C85.84	Other specified types of non-hodgkin lymphoma, lymph nodes of axilla and upper limb
C85.85	Other specified types of non-hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C85.86	Other specified types of non-hodgkin lymphoma, intrapelvic lymph nodes
C85.87	Other specified types of non-hodgkin lymphoma, spleen
C85.88	Other specified types of non-hodgkin lymphoma, lymph nodes of multiple sites
C85.89	Other specified types of non-hodgkin lymphoma, extranodal and solid organ sites
C85.9	Non-hodgkin lymphoma, unspecified
C85.90	Non-hodgkin lymphoma, unspecified, unspecified site
C85.91	Non-hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck
C85.92	Non-hodgkin lymphoma, unspecified, intrathoracic lymph nodes
C85.93	Non-hodgkin lymphoma, unspecified, intra-abdominal lymph nodes
C85.94	Non-hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb
C85.95	Non-hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C85.96	Non-hodgkin lymphoma, unspecified, intrapelvic lymph nodes
C85.97	Non-hodgkin lymphoma, unspecified, spleen
C85.98	Non-hodgkin lymphoma, unspecified, lymph nodes of multiple sites
C85.99	Non-hodgkin lymphoma, unspecified, extranodal and solid organ sites
C86	Other specified types of t/Nk-cell lymphoma
C86.0	Extranodal Nk/t-cell lymphoma, nasal type
C86.1	Hepatosplenic t-cell lymphoma
C86.2	Enteropathy-type (intestinal) t-cell lymphoma
C86.3	Subcutaneous panniculitis-like t-cell lymphoma
C86.4	Blastic Nk-cell lymphoma
C86.5	Angioimmunoblastic t-cell lymphoma
C86.6	Primary cutaneous Cd30-positive t-cell proliferations
C88.0	Waldenstrom macroglobulinemia
C88.4	Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue [MALt-lymphoma]
C91.5	Adult t-cell lymphoma/leukemia (HTLv-1-associated)
C91.50	Adult t-cell lymphoma/leukemia (HTLv-1-associated) not having achieved remission
Ocular inflammation
H57.8	Other specified disorders of eye and adnexa
T86.840	Corneal transplant rejection
T86.8401	Corneal transplant rejection, right eye
T86.8402	Corneal transplant rejection, left eye
T86.8403	Corneal transplant rejection, bilateral
T86.8409	Corneal transplant rejection, unspecified eye
T86.841	Corneal transplant failure
T86.8411	Corneal transplant failure, right eye
T86.8412	Corneal transplant failure, left eye
T86.8413	Corneal transplant failure, bilateral
T86.8419	Corneal transplant failure, unspecified eye
T86.842	Corneal transplant infection
T86.8421	Corneal transplant infection, right eye
T86.8422	Corneal transplant infection, left eye
T86.8423	Corneal transplant infection, bilateral
T86.8429	Corneal transplant infection, unspecified eye
Organ transplant rejection
T86.01	Bone marrow transplant rejection
T86.11	Kidney transplant rejection
T86.21	Heart transplant rejection
T86.31	Heart-lung transplant rejection
T86.41	Liver transplant rejection
T86.810	Lung transplant rejection
T86.820	Skin graft (allograft) rejection
T86.830	Bone graft rejection
T86.840	Corneal transplant rejection
T86.850	Intestine transplant rejection
T86.890	Other transplanted tissue rejection
T86.91	Unspecified transplanted organ and tissue rejection
Pemphigus
L10	Pemphigus
L10.0	Pemphigus vulgaris
L10.1	Pemphigus vegetans
L10.2	Pemphigus foliaceous
L10.3	Brazilian pemphigus [fogo selvagem]
L10.4	Pemphigus erythematosus
L10.5	Drug-induced pemphigus
L10.8	Other pemphigus
L10.81	Paraneoplastic pemphigus
L10.89	Other pemphigus
L10.9	Pemphigus, unspecified
Post traumatic osteoarthritis
M16.4	Bilateral post-traumatic osteoarthritis of hip
M16.5	Unilateral post-traumatic osteoarthritis of hip
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip
M16.51	Unilateral post-traumatic osteoarthritis, right hip
M16.52	Unilateral post-traumatic osteoarthritis, left hip
M17.2	Bilateral post-traumatic osteoarthritis of knee
M17.3	Unilateral post-traumatic osteoarthritis of knee
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee
M17.31	Unilateral post-traumatic osteoarthritis, right knee
M17.32	Unilateral post-traumatic osteoarthritis, left knee
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints
M18.3	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand
M19.1	Post-traumatic osteoarthritis of other joints
M19.11	Post-traumatic osteoarthritis, shoulder
M19.111	Post-traumatic osteoarthritis, right shoulder
M19.112	Post-traumatic osteoarthritis, left shoulder
M19.119	Post-traumatic osteoarthritis, unspecified shoulder
M19.12	Post-traumatic osteoarthritis, elbow
M19.121	Post-traumatic osteoarthritis, right elbow
M19.122	Post-traumatic osteoarthritis, left elbow
M19.129	Post-traumatic osteoarthritis, unspecified elbow
M19.13	Post-traumatic osteoarthritis, wrist
M19.131	Post-traumatic osteoarthritis, right wrist
M19.132	Post-traumatic osteoarthritis, left wrist
M19.139	Post-traumatic osteoarthritis, unspecified wrist
M19.14	Post-traumatic osteoarthritis, hand
M19.141	Post-traumatic osteoarthritis, right hand
M19.142	Post-traumatic osteoarthritis, left hand
M19.149	Post-traumatic osteoarthritis, unspecified hand
M19.17	Post-traumatic osteoarthritis, ankle and foot
M19.171	Post-traumatic osteoarthritis, right ankle and foot
M19.172	Post-traumatic osteoarthritis, left ankle and foot
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot
M19.19	Post-traumatic osteoarthritis, other specified site
M19.92	Post-traumatic osteoarthritis, unspecified site
Psoriasis
L40	Psoriasis
L40.0	Psoriasis vulgaris
L40.1	Generalized pustular psoriasis
L40.2	Acrodermatitis continua
L40.3	Pustulosis palmaris et plantaris
L40.4	Guttate psoriasis
L40.5	Arthropathic psoriasis
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.54	Psoriatic juvenile arthropathy
L40.59	Other psoriatic arthropathy
L40.8	Other psoriasis
L40.9	Psoriasis, unspecified
Psoriatic arthritis
L40.5	Arthropathic psoriasis
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.52	Psoriatic arthritis mutilans
L40.53	Psoriatic spondylitis
L40.54	Psoriatic juvenile arthropathy
L40.59	Other psoriatic arthropathy
Pure red cell aplasia
D60	Acquired pure red cell aplasia [erythroblastopenia]
D60.0	Chronic acquired pure red cell aplasia
D60.1	Transient acquired pure red cell aplasia
D60.8	Other acquired pure red cell aplasias
D60.9	Acquired pure red cell aplasia, unspecified
D61.01	Constitutional (pure) red blood cell aplasia
Rheumatoid arthritis
M05	Rheumatoid arthritis with rheumatoid factor
M05.0	Felty's syndrome
M05.00	Felty's syndrome, unspecified site
M05.01	Felty's syndrome, shoulder
M05.011	Felty's syndrome, right shoulder
M05.012	Felty's syndrome, left shoulder
M05.019	Felty's syndrome, unspecified shoulder
M05.02	Felty's syndrome, elbow
M05.021	Felty's syndrome, right elbow
M05.022	Felty's syndrome, left elbow
M05.029	Felty's syndrome, unspecified elbow
M05.03	Felty's syndrome, wrist
M05.031	Felty's syndrome, right wrist
M05.032	Felty's syndrome, left wrist
M05.039	Felty's syndrome, unspecified wrist
M05.04	Felty's syndrome, hand
M05.041	Felty's syndrome, right hand
M05.042	Felty's syndrome, left hand
M05.049	Felty's syndrome, unspecified hand
M05.05	Felty's syndrome, hip
M05.051	Felty's syndrome, right hip
M05.052	Felty's syndrome, left hip
M05.059	Felty's syndrome, unspecified hip
M05.06	Felty's syndrome, knee
M05.061	Felty's syndrome, right knee
M05.062	Felty's syndrome, left knee
M05.069	Felty's syndrome, unspecified knee
M05.07	Felty's syndrome, ankle and foot
M05.071	Felty's syndrome, right ankle and foot
M05.072	Felty's syndrome, left ankle and foot
M05.079	Felty's syndrome, unspecified ankle and foot
M05.09	Felty's syndrome, multiple sites
M05.1	Rheumatoid lung disease with rheumatoid arthritis
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site
M05.11	Rheumatoid lung disease with rheumatoid arthritis of shoulder
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder
M05.12	Rheumatoid lung disease with rheumatoid arthritis of elbow
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow
M05.13	Rheumatoid lung disease with rheumatoid arthritis of wrist
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist
M05.14	Rheumatoid lung disease with rheumatoid arthritis of hand
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand
M05.15	Rheumatoid lung disease with rheumatoid arthritis of hip
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip
M05.16	Rheumatoid lung disease with rheumatoid arthritis of knee
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee
M05.17	Rheumatoid lung disease with rheumatoid arthritis of ankle and foot
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites
M05.2	Rheumatoid vasculitis with rheumatoid arthritis
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site
M05.21	Rheumatoid vasculitis with rheumatoid arthritis of shoulder
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder
M05.22	Rheumatoid vasculitis with rheumatoid arthritis of elbow
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow
M05.23	Rheumatoid vasculitis with rheumatoid arthritis of wrist
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist
M05.24	Rheumatoid vasculitis with rheumatoid arthritis of hand
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand
M05.25	Rheumatoid vasculitis with rheumatoid arthritis of hip
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip
M05.26	Rheumatoid vasculitis with rheumatoid arthritis of knee
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee
M05.27	Rheumatoid vasculitis with rheumatoid arthritis of ankle and foot
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites
M05.3	Rheumatoid heart disease with rheumatoid arthritis
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site
M05.31	Rheumatoid heart disease with rheumatoid arthritis of shoulder
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder
M05.32	Rheumatoid heart disease with rheumatoid arthritis of elbow
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow
M05.33	Rheumatoid heart disease with rheumatoid arthritis of wrist
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.34	Rheumatoid heart disease with rheumatoid arthritis of hand
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.35	Rheumatoid heart disease with rheumatoid arthritis of hip
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.36	Rheumatoid heart disease with rheumatoid arthritis of knee
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee
M05.37	Rheumatoid heart disease with rheumatoid arthritis of ankle and foot
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites
M05.4	Rheumatoid myopathy with rheumatoid arthritis
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site
M05.41	Rheumatoid myopathy with rheumatoid arthritis of shoulder
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder
M05.42	Rheumatoid myopathy with rheumatoid arthritis of elbow
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow
M05.43	Rheumatoid myopathy with rheumatoid arthritis of wrist
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist
M05.44	Rheumatoid myopathy with rheumatoid arthritis of hand
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand
M05.45	Rheumatoid myopathy with rheumatoid arthritis of hip
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip
M05.46	Rheumatoid myopathy with rheumatoid arthritis of knee
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee
M05.47	Rheumatoid myopathy with rheumatoid arthritis of ankle and foot
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites
M05.5	Rheumatoid polyneuropathy with rheumatoid arthritis
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site
M05.51	Rheumatoid polyneuropathy with rheumatoid arthritis of shoulder
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder
M05.52	Rheumatoid polyneuropathy with rheumatoid arthritis of elbow
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow
M05.53	Rheumatoid polyneuropathy with rheumatoid arthritis of wrist
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist
M05.54	Rheumatoid polyneuropathy with rheumatoid arthritis of hand
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand
M05.55	Rheumatoid polyneuropathy with rheumatoid arthritis of hip
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip
M05.56	Rheumatoid polyneuropathy with rheumatoid arthritis of knee
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee
M05.57	Rheumatoid polyneuropathy with rheumatoid arthritis of ankle and foot
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites
M05.6	Rheumatoid arthritis with involvement of other organs and systems
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems
M05.61	Rheumatoid arthritis of shoulder with involvement of other organs and systems
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems
M05.62	Rheumatoid arthritis of elbow with involvement of other organs and systems
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems
M05.63	Rheumatoid arthritis of wrist with involvement of other organs and systems
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems
M05.64	Rheumatoid arthritis of hand with involvement of other organs and systems
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems
M05.65	Rheumatoid arthritis of hip with involvement of other organs and systems
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems
M05.66	Rheumatoid arthritis of knee with involvement of other organs and systems
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems
M05.67	Rheumatoid arthritis of ankle and foot with involvement of other organs and systems
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems
M05.7	Rheumatoid arthritis with rheumatoid factor without organ or systems involvement
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement
M05.71	Rheumatoid arthritis with rheumatoid factor of shoulder without organ or systems involvement
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement
M05.72	Rheumatoid arthritis with rheumatoid factor of elbow without organ or systems involvement
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement
M05.73	Rheumatoid arthritis with rheumatoid factor of wrist without organ or systems involvement
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement
M05.74	Rheumatoid arthritis with rheumatoid factor of hand without organ or systems involvement
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement
M05.75	Rheumatoid arthritis with rheumatoid factor of hip without organ or systems involvement
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement
M05.76	Rheumatoid arthritis with rheumatoid factor of knee without organ or systems involvement
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement
M05.77	Rheumatoid arthritis with rheumatoid factor of ankle and foot without organ or systems involvement
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement
M05.8	Other rheumatoid arthritis with rheumatoid factor
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site
M05.81	Other rheumatoid arthritis with rheumatoid factor of shoulder
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder
M05.82	Other rheumatoid arthritis with rheumatoid factor of elbow
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow
M05.83	Other rheumatoid arthritis with rheumatoid factor of wrist
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist
M05.84	Other rheumatoid arthritis with rheumatoid factor of hand
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand
M05.85	Other rheumatoid arthritis with rheumatoid factor of hip
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip
M05.86	Other rheumatoid arthritis with rheumatoid factor of knee
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee
M05.87	Other rheumatoid arthritis with rheumatoid factor of ankle and foot
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified
M06	Other rheumatoid arthritis
M06.0	Rheumatoid arthritis without rheumatoid factor
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site
M06.01	Rheumatoid arthritis without rheumatoid factor, shoulder
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder
M06.02	Rheumatoid arthritis without rheumatoid factor, elbow
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow
M06.03	Rheumatoid arthritis without rheumatoid factor, wrist
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist
M06.04	Rheumatoid arthritis without rheumatoid factor, hand
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand
M06.05	Rheumatoid arthritis without rheumatoid factor, hip
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip
M06.06	Rheumatoid arthritis without rheumatoid factor, knee
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee
M06.07	Rheumatoid arthritis without rheumatoid factor, ankle and foot
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site
M06.8	Other specified rheumatoid arthritis
M06.80	Other specified rheumatoid arthritis, unspecified site
M06.81	Other specified rheumatoid arthritis, shoulder
M06.811	Other specified rheumatoid arthritis, right shoulder
M06.812	Other specified rheumatoid arthritis, left shoulder
M06.819	Other specified rheumatoid arthritis, unspecified shoulder
M06.82	Other specified rheumatoid arthritis, elbow
M06.821	Other specified rheumatoid arthritis, right elbow
M06.822	Other specified rheumatoid arthritis, left elbow
M06.829	Other specified rheumatoid arthritis, unspecified elbow
M06.83	Other specified rheumatoid arthritis, wrist
M06.831	Other specified rheumatoid arthritis, right wrist
M06.832	Other specified rheumatoid arthritis, left wrist
M06.839	Other specified rheumatoid arthritis, unspecified wrist
M06.84	Other specified rheumatoid arthritis, hand
M06.841	Other specified rheumatoid arthritis, right hand
M06.842	Other specified rheumatoid arthritis, left hand
M06.849	Other specified rheumatoid arthritis, unspecified hand
M06.85	Other specified rheumatoid arthritis, hip
M06.851	Other specified rheumatoid arthritis, right hip
M06.852	Other specified rheumatoid arthritis, left hip
M06.859	Other specified rheumatoid arthritis, unspecified hip
M06.86	Other specified rheumatoid arthritis, knee
M06.861	Other specified rheumatoid arthritis, right knee
M06.862	Other specified rheumatoid arthritis, left knee
M06.869	Other specified rheumatoid arthritis, unspecified knee
M06.87	Other specified rheumatoid arthritis, ankle and foot
M06.871	Other specified rheumatoid arthritis, right ankle and foot
M06.872	Other specified rheumatoid arthritis, left ankle and foot
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot
M06.88	Other specified rheumatoid arthritis, vertebrae
M06.89	Other specified rheumatoid arthritis, multiple sites
M06.8A	Other specified rheumatoid arthritis, other specified site
M06.9	Rheumatoid arthritis, unspecified
Sarcoidosis
D86	Sarcoidosis
D86.0	Sarcoidosis of lung
D86.1	Sarcoidosis of lymph nodes
D86.2	Sarcoidosis of lung with sarcoidosis of lymph nodes
D86.3	Sarcoidosis of skin
D86.8	Sarcoidosis of other sites
D86.81	Sarcoid meningitis
D86.82	Multiple cranial nerve palsies in sarcoidosis
D86.83	Sarcoid iridocyclitis
D86.84	Sarcoid pyelonephritis
D86.85	Sarcoid myocarditis
D86.86	Sarcoid arthropathy
D86.87	Sarcoid myositis
D86.89	Sarcoidosis of other sites
D86.9	Sarcoidosis, unspecified
Serum sickness
T80.6	Other serum reactions
Status asthmaticus
J45.22	Mild intermittent asthma with status asthmaticus
J45.32	Mild persistent asthma with status asthmaticus
J45.42	Moderate persistent asthma with status asthmaticus
J45.52	Severe persistent asthma with status asthmaticus
J45.902	Unspecified asthma with status asthmaticus
Synovitis
M65.4	Radial styloid tenosynovitis [de quervain]
M65.8	Other synovitis and tenosynovitis
M65.80	Other synovitis and tenosynovitis, unspecified site
M65.81	Other synovitis and tenosynovitis, shoulder
M65.811	Other synovitis and tenosynovitis, right shoulder
M65.812	Other synovitis and tenosynovitis, left shoulder
M65.819	Other synovitis and tenosynovitis, unspecified shoulder
M65.82	Other synovitis and tenosynovitis, upper arm
M65.821	Other synovitis and tenosynovitis, right upper arm
M65.822	Other synovitis and tenosynovitis, left upper arm
M65.829	Other synovitis and tenosynovitis, unspecified upper arm
M65.83	Other synovitis and tenosynovitis, forearm
M65.831	Other synovitis and tenosynovitis, right forearm
M65.832	Other synovitis and tenosynovitis, left forearm
M65.839	Other synovitis and tenosynovitis, unspecified forearm
M65.84	Other synovitis and tenosynovitis, hand
M65.841	Other synovitis and tenosynovitis, right hand
M65.842	Other synovitis and tenosynovitis, left hand
M65.849	Other synovitis and tenosynovitis, unspecified hand
M65.85	Other synovitis and tenosynovitis, thigh
M65.851	Other synovitis and tenosynovitis, right thigh
M65.852	Other synovitis and tenosynovitis, left thigh
M65.859	Other synovitis and tenosynovitis, unspecified thigh
M65.86	Other synovitis and tenosynovitis, lower leg
M65.861	Other synovitis and tenosynovitis, right lower leg
M65.862	Other synovitis and tenosynovitis, left lower leg
M65.869	Other synovitis and tenosynovitis, unspecified lower leg
M65.87	Other synovitis and tenosynovitis, ankle and foot
M65.871	Other synovitis and tenosynovitis, right ankle and foot
M65.872	Other synovitis and tenosynovitis, left ankle and foot
M65.879	Other synovitis and tenosynovitis, unspecified ankle and foot
M65.88	Other synovitis and tenosynovitis, other site
M65.89	Other synovitis and tenosynovitis, multiple sites
M65.9	Synovitis and tenosynovitis, unspecified
M65.90	Unspecified synovitis and tenosynovitis, unspecified site
M65.91	Unspecified synovitis and tenosynovitis, shoulder
M65.911	Unspecified synovitis and tenosynovitis, right shoulder
M65.912	Unspecified synovitis and tenosynovitis, left shoulder
M65.919	Unspecified synovitis and tenosynovitis, unspecified shoulder
M65.92	Unspecified synovitis and tenosynovitis, upper arm
M65.921	Unspecified synovitis and tenosynovitis, right upper arm
M65.922	Unspecified synovitis and tenosynovitis, left upper arm
M65.929	Unspecified synovitis and tenosynovitis, unspecified upper arm
M65.93	Unspecified synovitis and tenosynovitis, forearm
M65.931	Unspecified synovitis and tenosynovitis, right forearm
M65.932	Unspecified synovitis and tenosynovitis, left forearm
M65.939	Unspecified synovitis and tenosynovitis, unspecified forearm
M65.94	Unspecified synovitis and tenosynovitis, hand
M65.941	Unspecified synovitis and tenosynovitis, right hand
M65.942	Unspecified synovitis and tenosynovitis, left hand
M65.949	Unspecified synovitis and tenosynovitis, unspecified hand
M65.95	Unspecified synovitis and tenosynovitis, thigh
M65.951	Unspecified synovitis and tenosynovitis, right thigh
M65.952	Unspecified synovitis and tenosynovitis, left thigh
M65.959	Unspecified synovitis and tenosynovitis, unspecified thigh
M65.96	Unspecified synovitis and tenosynovitis, lower leg
M65.961	Unspecified synovitis and tenosynovitis, right lower leg
M65.962	Unspecified synovitis and tenosynovitis, left lower leg
M65.969	Unspecified synovitis and tenosynovitis, unspecified lower leg
M65.97	Unspecified synovitis and tenosynovitis, ankle and foot
M65.971	Unspecified synovitis and tenosynovitis, right ankle and foot
M65.972	Unspecified synovitis and tenosynovitis, left ankle and foot
M65.979	Unspecified synovitis and tenosynovitis, unspecified ankle and foot
M65.98	Unspecified synovitis and tenosynovitis, other site
M65.99	Unspecified synovitis and tenosynovitis, multiple sites
Synovitis due to osteoarthritis
M65.8	Other synovitis and tenosynovitis
M65.80	Other synovitis and tenosynovitis, unspecified site
M65.81	Other synovitis and tenosynovitis, shoulder
M65.811	Other synovitis and tenosynovitis, right shoulder
M65.812	Other synovitis and tenosynovitis, left shoulder
M65.819	Other synovitis and tenosynovitis, unspecified shoulder
M65.82	Other synovitis and tenosynovitis, upper arm
M65.821	Other synovitis and tenosynovitis, right upper arm
M65.822	Other synovitis and tenosynovitis, left upper arm
M65.829	Other synovitis and tenosynovitis, unspecified upper arm
M65.83	Other synovitis and tenosynovitis, forearm
M65.831	Other synovitis and tenosynovitis, right forearm
M65.832	Other synovitis and tenosynovitis, left forearm
M65.839	Other synovitis and tenosynovitis, unspecified forearm
M65.84	Other synovitis and tenosynovitis, hand
M65.841	Other synovitis and tenosynovitis, right hand
M65.842	Other synovitis and tenosynovitis, left hand
M65.849	Other synovitis and tenosynovitis, unspecified hand
M65.85	Other synovitis and tenosynovitis, thigh
M65.851	Other synovitis and tenosynovitis, right thigh
M65.852	Other synovitis and tenosynovitis, left thigh
M65.859	Other synovitis and tenosynovitis, unspecified thigh
M65.86	Other synovitis and tenosynovitis, lower leg
M65.861	Other synovitis and tenosynovitis, right lower leg
M65.862	Other synovitis and tenosynovitis, left lower leg
M65.869	Other synovitis and tenosynovitis, unspecified lower leg
M65.87	Other synovitis and tenosynovitis, ankle and foot
M65.871	Other synovitis and tenosynovitis, right ankle and foot
M65.872	Other synovitis and tenosynovitis, left ankle and foot
M65.879	Other synovitis and tenosynovitis, unspecified ankle and foot
M65.88	Other synovitis and tenosynovitis, other site
M65.89	Other synovitis and tenosynovitis, multiple sites
M65.9	Synovitis and tenosynovitis, unspecified
M65.951	Unspecified synovitis and tenosynovitis, right thigh
M65.952	Unspecified synovitis and tenosynovitis, left thigh
M65.959	Unspecified synovitis and tenosynovitis, unspecified thigh
M65.96	Unspecified synovitis and tenosynovitis, lower leg
M65.961	Unspecified synovitis and tenosynovitis, right lower leg
M65.962	Unspecified synovitis and tenosynovitis, left lower leg
M65.969	Unspecified synovitis and tenosynovitis, unspecified lower leg
M65.97	Unspecified synovitis and tenosynovitis, ankle and foot
M65.971	Unspecified synovitis and tenosynovitis, right ankle and foot
M65.972	Unspecified synovitis and tenosynovitis, left ankle and foot
M65.979	Unspecified synovitis and tenosynovitis, unspecified ankle and foot
M65.98	Unspecified synovitis and tenosynovitis, other site
M65.99	Unspecified synovitis and tenosynovitis, multiple sites
Systemic dermatomyositis
M33	Dermatopolymyositis
M33.0	Juvenile dermatomyositis
M33.00	Juvenile dermatomyositis, organ involvement unspecified
M33.01	Juvenile dermatomyositis with respiratory involvement
M33.02	Juvenile dermatomyositis with myopathy
M33.03	Juvenile dermatomyositis without myopathy
M33.09	Juvenile dermatomyositis with other organ involvement
M33.1	Other dermatomyositis
M33.10	Other dermatomyositis, organ involvement unspecified
M33.11	Other dermatomyositis with respiratory involvement
M33.12	Other dermatomyositis with myopathy
M33.13	Other dermatomyositis without myopathy
M33.19	Other dermatomyositis with other organ involvement
M33.9	Dermatopolymyositis, unspecified
M33.90	Dermatopolymyositis, unspecified, organ involvement unspecified
M33.91	Dermatopolymyositis, unspecified with respiratory involvement
M33.92	Dermatopolymyositis, unspecified with myopathy
M33.93	Dermatopolymyositis, unspecified without myopathy
M33.99	Dermatopolymyositis, unspecified with other organ involvement
M36.0	Dermato(poly)myositis in neoplastic disease
Systemic lupus erythematosus
M32	Systemic lupus erythematosus (SLe)
M32.0	Drug-induced systemic lupus erythematosus
M32.1	Systemic lupus erythematosus with organ or system involvement
M32.10	Systemic lupus erythematosus, organ or system involvement unspecified
M32.11	Endocarditis in systemic lupus erythematosus
M32.12	Pericarditis in systemic lupus erythematosus
M32.13	Lung involvement in systemic lupus erythematosus
M32.14	Glomerular disease in systemic lupus erythematosus
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus
M32.19	Other organ or system involvement in systemic lupus erythematosus
M32.8	Other forms of systemic lupus erythematosus
M32.9	Systemic lupus erythematosus, unspecified
Tendonitis
M75.2	Bicipital tendinitis
M75.20	Bicipital tendinitis, unspecified shoulder
M75.21	Bicipital tendinitis, right shoulder
M75.22	Bicipital tendinitis, left shoulder
M76.0	Gluteal tendinitis
M76.00	Gluteal tendinitis, unspecified hip
M76.01	Gluteal tendinitis, right hip
M76.02	Gluteal tendinitis, left hip
M76.1	Psoas tendinitis
M76.10	Psoas tendinitis, unspecified hip
M76.11	Psoas tendinitis, right hip
M76.12	Psoas tendinitis, left hip
M76.5	Patellar tendinitis
M76.50	Patellar tendinitis, unspecified knee
M76.51	Patellar tendinitis, right knee
M76.52	Patellar tendinitis, left knee
M76.6	Achilles tendinitis
M76.60	Achilles tendinitis, unspecified leg
M76.61	Achilles tendinitis, right leg
M76.62	Achilles tendinitis, left leg
M76.7	Peroneal tendinitis
M76.70	Peroneal tendinitis, unspecified leg
M76.71	Peroneal tendinitis, right leg
M76.72	Peroneal tendinitis, left leg
M76.82	Posterior tibial tendinitis
M76.821	Posterior tibial tendinitis, right leg
M76.822	Posterior tibial tendinitis, left leg
M76.829	Posterior tibial tendinitis, unspecified leg
Tenosynovitis
M65.4	Radial styloid tenosynovitis [de quervain]
M65.8	Other synovitis and tenosynovitis
M65.80	Other synovitis and tenosynovitis, unspecified site
M65.81	Other synovitis and tenosynovitis, shoulder
M65.811	Other synovitis and tenosynovitis, right shoulder
M65.812	Other synovitis and tenosynovitis, left shoulder
M65.819	Other synovitis and tenosynovitis, unspecified shoulder
M65.82	Other synovitis and tenosynovitis, upper arm
M65.821	Other synovitis and tenosynovitis, right upper arm
M65.822	Other synovitis and tenosynovitis, left upper arm
M65.829	Other synovitis and tenosynovitis, unspecified upper arm
M65.83	Other synovitis and tenosynovitis, forearm
M65.831	Other synovitis and tenosynovitis, right forearm
M65.832	Other synovitis and tenosynovitis, left forearm
M65.839	Other synovitis and tenosynovitis, unspecified forearm
M65.84	Other synovitis and tenosynovitis, hand
M65.841	Other synovitis and tenosynovitis, right hand
M65.842	Other synovitis and tenosynovitis, left hand
M65.849	Other synovitis and tenosynovitis, unspecified hand
M65.85	Other synovitis and tenosynovitis, thigh
M65.851	Other synovitis and tenosynovitis, right thigh
M65.852	Other synovitis and tenosynovitis, left thigh
M65.859	Other synovitis and tenosynovitis, unspecified thigh
M65.86	Other synovitis and tenosynovitis, lower leg
M65.861	Other synovitis and tenosynovitis, right lower leg
M65.862	Other synovitis and tenosynovitis, left lower leg
M65.869	Other synovitis and tenosynovitis, unspecified lower leg
M65.87	Other synovitis and tenosynovitis, ankle and foot
M65.871	Other synovitis and tenosynovitis, right ankle and foot
M65.872	Other synovitis and tenosynovitis, left ankle and foot
M65.879	Other synovitis and tenosynovitis, unspecified ankle and foot
M65.88	Other synovitis and tenosynovitis, other site
M65.89	Other synovitis and tenosynovitis, multiple sites
M65.9	Synovitis and tenosynovitis, unspecified
M65.90	Unspecified synovitis and tenosynovitis, unspecified site
M65.91	Unspecified synovitis and tenosynovitis, shoulder
M65.911	Unspecified synovitis and tenosynovitis, right shoulder
M65.912	Unspecified synovitis and tenosynovitis, left shoulder
M65.919	Unspecified synovitis and tenosynovitis, unspecified shoulder
M65.92	Unspecified synovitis and tenosynovitis, upper arm
M65.921	Unspecified synovitis and tenosynovitis, right upper arm
M65.922	Unspecified synovitis and tenosynovitis, left upper arm
M65.929	Unspecified synovitis and tenosynovitis, unspecified upper arm
M65.93	Unspecified synovitis and tenosynovitis, forearm
M65.931	Unspecified synovitis and tenosynovitis, right forearm
M65.932	Unspecified synovitis and tenosynovitis, left forearm
M65.939	Unspecified synovitis and tenosynovitis, unspecified forearm
M65.94	Unspecified synovitis and tenosynovitis, hand
M65.941	Unspecified synovitis and tenosynovitis, right hand
M65.942	Unspecified synovitis and tenosynovitis, left hand
M65.949	Unspecified synovitis and tenosynovitis, unspecified hand
M65.95	Unspecified synovitis and tenosynovitis, thigh
M65.951	Unspecified synovitis and tenosynovitis, right thigh
M65.952	Unspecified synovitis and tenosynovitis, left thigh
M65.959	Unspecified synovitis and tenosynovitis, unspecified thigh
M65.96	Unspecified synovitis and tenosynovitis, lower leg
M65.961	Unspecified synovitis and tenosynovitis, right lower leg
M65.962	Unspecified synovitis and tenosynovitis, left lower leg
M65.969	Unspecified synovitis and tenosynovitis, unspecified lower leg
M65.97	Unspecified synovitis and tenosynovitis, ankle and foot
M65.971	Unspecified synovitis and tenosynovitis, right ankle and foot
M65.972	Unspecified synovitis and tenosynovitis, left ankle and foot
M65.979	Unspecified synovitis and tenosynovitis, unspecified ankle and foot
M65.98	Unspecified synovitis and tenosynovitis, other site
M65.99	Unspecified synovitis and tenosynovitis, multiple sites
Thyroiditis
E06	Thyroiditis
E06.0	Acute thyroiditis
E06.1	Subacute thyroiditis
E06.2	Chronic thyroiditis with transient thyrotoxicosis
E06.3	Autoimmune thyroiditis
E06.4	Drug-induced thyroiditis
E06.5	Other chronic thyroiditis
E06.9	Thyroiditis, unspecified
Transfusion reaction urticaria
L50.0	Allergic urticaria
L50.8	Other urticaria
L50.9	Urticaria, unspecified
Trichinosis
B75	Trichinellosis
Ulcerative colitis
K51	Ulcerative colitis
K51.0	Ulcerative (chronic) pancolitis
K51.00	Ulcerative (chronic) pancolitis without complications
K51.01	Ulcerative (chronic) pancolitis with complications
K51.011	Ulcerative (chronic) pancolitis with rectal bleeding
K51.012	Ulcerative (chronic) pancolitis with intestinal obstruction
K51.013	Ulcerative (chronic) pancolitis with fistula
K51.014	Ulcerative (chronic) pancolitis with abscess
K51.018	Ulcerative (chronic) pancolitis with other complication
K51.019	Ulcerative (chronic) pancolitis with unspecified complications
K51.2	Ulcerative (chronic) proctitis
K51.20	Ulcerative (chronic) proctitis without complications
K51.21	Ulcerative (chronic) proctitis with complications
K51.211	Ulcerative (chronic) proctitis with rectal bleeding
K51.212	Ulcerative (chronic) proctitis with intestinal obstruction
K51.213	Ulcerative (chronic) proctitis with fistula
K51.214	Ulcerative (chronic) proctitis with abscess
K51.218	Ulcerative (chronic) proctitis with other complication
K51.219	Ulcerative (chronic) proctitis with unspecified complications
K51.3	Ulcerative (chronic) rectosigmoiditis
K51.30	Ulcerative (chronic) rectosigmoiditis without complications
K51.31	Ulcerative (chronic) rectosigmoiditis with complications
K51.311	Ulcerative (chronic) rectosigmoiditis with rectal bleeding
K51.312	Ulcerative (chronic) rectosigmoiditis with intestinal obstruction
K51.313	Ulcerative (chronic) rectosigmoiditis with fistula
K51.314	Ulcerative (chronic) rectosigmoiditis with abscess
K51.318	Ulcerative (chronic) rectosigmoiditis with other complication
K51.319	Ulcerative (chronic) rectosigmoiditis with unspecified complications
K51.5	Left sided colitis
K51.50	Left sided colitis without complications
K51.51	Left sided colitis with complications
K51.511	Left sided colitis with rectal bleeding
K51.512	Left sided colitis with intestinal obstruction
K51.513	Left sided colitis with fistula
K51.514	Left sided colitis with abscess
K51.518	Left sided colitis with other complication
K51.519	Left sided colitis with unspecified complications
K51.8	Other ulcerative colitis
K51.80	Other ulcerative colitis without complications
K51.81	Other ulcerative colitis with complications
K51.811	Other ulcerative colitis with rectal bleeding
K51.812	Other ulcerative colitis with intestinal obstruction
K51.813	Other ulcerative colitis with fistula
K51.814	Other ulcerative colitis with abscess
K51.818	Other ulcerative colitis with other complication
K51.819	Other ulcerative colitis with unspecified complications
K51.9	Ulcerative colitis, unspecified
K51.90	Ulcerative colitis, unspecified, without complications
K51.91	Ulcerative colitis, unspecified, with complications
K51.911	Ulcerative colitis, unspecified with rectal bleeding
K51.912	Ulcerative colitis, unspecified with intestinal obstruction
K51.913	Ulcerative colitis, unspecified with fistula
K51.914	Ulcerative colitis, unspecified with abscess
K51.918	Ulcerative colitis, unspecified with other complication
K51.919	Ulcerative colitis, unspecified with unspecified complications